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ABSTRACT 
This dissertation entails the immobilization of heparin to 
polymer substrates and the characterization of the resultant hep-
arin immobilized surfaces. To prevent crosslinking, all deriva-
tization and immobilization reactions were conducted with N-
acetylated heparin. 
Preliminary heparin derivatization studies demonstrated that 
carboxylic groups could be utilized in the covalent immobiliza-
tion reactions if the number of participating carboxylic groups 
was minimized. 
It was found that the anticoagulant activity of the immobi-
lized heparin increased with increasing spacer group length 
separating the immobilized heparin from the polymer surface. 
X-ray photoelectron spectroscopy revealed that the immobi-
lized heparin was not associated with the surfaces of adsorbed 
protein layers following contact with protein solutions or plasma. 
These results suggested that the immobilized heparin was 
masked from platelets and unable to directly interact with plate-
lets as is the case with soluble heparin. This hypothesis was 
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CHAPTER 1 
INTRODUCTION 
1.1 Commercial Preparation 
Heparin is the most commonly used anticoagulant. Since first 
becoming commercially available in the late 1930's (1), more than 
6 metric tons are now annually produced primarily from bovine lung 
and bovine and porcine intestinal mucosa (2). Heparin is produced 
by mast cells as a macromolecular complex composed of linear poly-
anionic carbohydrate chains covalently linked to a protein core, 
the total molecular weight of the macromolecular complex ranging 
from 750,000 to 1,000,000 (3). The separation and purification of 
heparin is complicated by the presence in the same source tissues 
of compounds possessing similar chemical and physical properties, 
but with no anticoagulant activity (4). These compounds, in-
cluding hyaluronic acid, chrondroitin sulfates A, B, C and D, and 
keratin sulfate, also exist in the native state as covalently con-
jugated proteo-glycuronans and heparin composes less than 1% of 
that mixture (5). The protein moiety is removed either by alka-
line or enzymatic hydrolytic cleavage to yield a glycosamino-
giycuronan mixture from which commercial heparin is separated. 
Although it has been generally accepted that mast cells were the 
only certain source of the native heparin protein complex, recent 
studies have shown the existence of heparin-protein complexes in 
liver and muscle tissues (6) and evidence for the existence of a 
placental heparin-protein complex (7,8). However, none of these 
sources are of commercial importance. 
1.2 Chemical Structure 
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Commercial heparin preparations exist as a population of sul-
foglucosamine and hexuronic acid units linked by 1-4 glycosidic 
bonds to form linear anionic carbohydrate molecules ranging in 
molecular wieght from less than 10,000 to greater than 20,000 (9, 
10). Degradation of commercial heparin by enzymes of Flavor-
bacterium heparinum has revealed that over 90% of the total hepa-
rin preparation exists as a hexasaccharide containing 2,6-
disulfoglucosamine, 2-sulfoiduronic acid and glucuronic acid in 
3:2:1 proportions respectively (2). Biosynthesis studies have 
shown that single sugar units in the heparin hexasaccharide chain 
can vary; for example, both su1famino, acetylamino and free amino 
glucosamine may occur and iduronic and glucuronic acid may occur 
in both sulfated and unsulfated forms (11). Changes in any of the 
above structural parameters correlated at best with limited suc-
cess to the anticoagulant activity of heparin. 
Individual sugar unit variations, combined with the large mo-
lecular weight variations among heparin molecules within a commer-
cial preparation, leads to a high degree of polydispersity. The 
high polydispersity of heparin, in size and chemical structure, is 
born out by findings that after electrophoresis and staining with 
toluidine blue, a basic dye that complexes acidic components in-
cluding heparin, at least 21 types of heparin molecules can be 
isolated with the same charge and the molecular weight of those 
components ranges from 3,000 to 37,500 (3). 
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In view of the ill-defined chemical structure of heparin, 
numerous investigators have considered the possibility that the 
anticoagulant activity of heparin preparations is associated with 
only a small fraction of the total heparin molecules present in a 
given preparation, the remaining molecules representing gross im-
purities, an analogous situation to the separation and purifica-
tion of commercial heparin from the mixture at glycosaminogly-
curonans. In an attempt to isolate an homogenous heparin species 
which could be correlated to the anticoagulant activity of heparin 
preparations, a large excess of antithrombin III (ATIII), the rel-
evance of ATIII to heparin anticoagulant activity is described be-
low, was added to a commercial heparin preparation. Subsequent 
sucrose gradient centrifugation revealed two distinct populations 
of heparin, one population that bound ATIII and a second popula-
tion did not bind ATIII (12). The ATIII binding heparin popula-
tion represented less than one-third of the heparin preparation 
yet it possessed over 85% of the total anticoagulant activity of 
the starting material. These active heparin species also proved 
to be highly polydispersed, ranging in molecular weight from 
~ 7,000 to ~ 20,000. Detailed chemical-structural analysis of 
molecular weight fractions obtained from active (binds ATIII) and 
inactive (does not bind ATIII) heparin populations revealed the 
existence at a unique tetrasaccharide sequence present in the 
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active heparin population (13,14). The tetrasaccharide sequence, 
L-iduronic acid + N-acetylate-D-glucosamine 6-sulfate + 
D-glucuronic acid + N-sulfated-D-glucosamine 6-sulfate, was found 
in only 2.6% of the molecules present in the inactive heparin 
population while every molecule in the active population possess 
at least one tetrasaccharide sequence (13). Paradoxically, the 
L-iduronic acid is not sulfated in the ATIII binding tetrasac-
charide sequence, the vast majority of those sugar units being 
present as 2-sulfoiduronic acid, and the relative abundance of 
sulfates in the tetrasaccharide sequence is substantially lower 
than for the bulk heparin preparation; yet it has long been estab-
lished that minimal heparin desulfination leads to a rapid loss in 
anticoagulant activity (15). 
The correlation between the relative abundance of the unique 
tetrasaccharide sequence and the anticoagulant activity strongly 
suggests that this sequence represents the ATIII binding site. 
This contention is further supported by findings that the tetra-
saccharide sequence is protected from the enzymatic degradative 
action of bacterial heparinase when the active heparin molecules 
are in contact with ATIII (14). 
A composite chemical structure for heparin begins to emerge, 
heparin being composed primarily of the previously mentioned hexa-
saccharide units, which can vary considerably in individual sugar 
unit structure, with sporadically located ATIII binding tetra-
saccharide units. The hexasacchride sequence and the ATIII bind-
































































tion of these two sequences appears possible; however, only mole-
cules with at least one ATIII binding sequence possess anti-
coagulant activity. 
Other chemical groups are also observed in heparin structure 
only to a much smaller extent. It has been shown that commercial 
heparin also contains between 0.3% and 2.3%, depending upon the 
source, amino acids. Of those amino acids, glycine is the most 
prominent, followed by cysteic acid, alanine, aspartic acid and 
serine in that order of abundance (12). These amino acids can be 
covalently linked to heparin, in the specific case of aspartic 
acid being linked via an N-glycosyl bond between the carboxylic 
groups on aspartic acid to amino groups of hexosamines, or they 
may simply be ionically bound and represent impurities from the 
native heparin protein moiety. 
6 
In an attempt to correlate heparin structural parameters to 
its anticoagulant activity, numerous investigators have prepared 
synthetic heparinoids, primarily linear sulfated carbohydrates 
(16,17). Although these materials mimic heparin to limited de-
grees, they do not appear to act with coagulation factors to the 
same extent as heparin, leading to reduced potency relative to 
heparin. A novel approach to synthetic heparinoids has recently 
been reported, where the double bonds in cis-polyisoprene are con-
verted to adjacent N-sulfates and carboxylic functional groups to 
provide an improved structural similarity to heparin (18). These 
materials have improved anticoagulant potency; however, they still 
do not interact with coagulation factors in an identical manner as 
7 
heparin, as evidenced by differences in activities with different 
coagulation assays. 
Heparin has been shown to complex with different coagulation 
factors, such as thrombin, ATIII, factor Xa, platelet factors and 
numerous enzymes as discussed below. It is apparent that heparin 
must possess multiple structural domains for interaction with 
these various factors. Isolation of the ATIII binding site of 
heparin does not, by itself, describe the structural requirements 
for the ~ vivo anticoagulant effect of heparin. Carbohydrate 
sequences residing outside of the primary ATIII binding tetrasac-
charide sequence may play an important role in the anticoagulant 
activity of heparin. Furthermore, spatial orientations of these 
structural domains must also play an essential role in the anti-
coagulant activity. An example of these conformational require-
ments for the structural domains is provided in the ATIII binding 
tetrasaccharide. As previously mentioned, the iduronic acid in 
the tetrasaccharide ;s not sulfated while the majority of iduronic 
acid residues of heparin are sulfated. Su1foiduronic acid ;s re-
ported to possess only one stable conformational state while 
iduronic acid can assume three different conformations (19). 
To better understand the structural requirements correlating 
to the anticoagulant activity, the dynamic conformational struc-
tures must also be considered. Undoubtedly, future work will re-
veal more information with these regards. 
1.3 Heparin Pharmacology 
Heparin exerts its anticoagulant effect by preventing the 
conversion of fibrinogen to fibrin via the proteolytic enzyme 
thrombin. The formation of thrombin occurs primarily via two 
pathways, intrinsic and extrinsic, in which activation of zymogen 
plasma coagulation factors initiates activation of subsequent 
factors in the progression of each pathway. This cascade of se-
quential coagulation factor activations is presented in Figures 2 
and 3. 
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Activation of the intrinsic pathway is initiated by conver-
sion of factor XII (Hageman factor) to the proteolytic active 
species factor XIIa. This initial activation step can occur 
through a variety of stimulants, the most common being through in-
teraction with exposed collagen brought about following injury to 
the endothelial cell lining of the vascular intima (20). Other 
stimulants are also known to activate factor XII, including ad-
sorption onto negatively charged foreign surfaces (20). Factor 
XII interactions with negatively charged surfaces can result in 
the formation of two active species (21), one which remains bound 
to the surface and can activate subsequent factors, factor XI as 
described below, only if they too are surface associated, and the 
second being a soluble factor XIIa fragment which will not acti-
vate factor XI. This factor XIla fragment will, however, induce 
conversion of prekallikrein to kallikrein, a proteolytic enzyme 
which can cleave high molecular weight kininogens into bradykinin, 
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Figure 3. Extrinsic Coagulation Pathway 
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factor XI to factor Xla which subsequently converts factor IX to 
factor IXa. Factor IXa combines with lipids (platelets) and a co-
factor, factor VIlla, to form a complex that converts factor X to 
factor Xa (20,22). Once factor Xa has been produced, it combines 
with phosopholipid surfaces (platelet membranes) and factor Va to 
form a complex that insures rapid conversion of prothrombin to 
thrombin. Although the formation of the factor Xa:factor Va: 
phospholipid surface complex is not absolutely necessary for con-
version of prothrombin to thrombin by factor Xa, prothrombin acti-
vation kinetics are much more rapid in the presence of the phos-
pholipid surface and factor VIlla cofactors (22). Thrombin in 
turn converts fibrinogen to fibrin monomer which is then cross-
linked into a fibrin network by factor XIII. 
Activation of the extrinsic pathway is initiated by tissue 
injury with resultant release of a protein-lipid tissue factor, 
which is not yet completely identified, that combines with factor 
VII (23) to form a complex that converts factor X to factor Xa and 
conversion of prothrombin to thrombin occurs through the pathway 
previously described. 
Platelets can also initiate activation of prothrombin by re-
lease of platelet factor 3, a substance believed to be associated 
with the platelet membrane (24). 
Activation of coagulation mechanisms is modulated by the pre-
sence of several natural inhibitors, antithrombins (AT), in blood. 
These antithrombins serve a vital function; for in their absence, 
once prothrombin is converted to thrombin, 10 ml of blood would 
contain a sufficient quantity of thrombin to clot all of the 
fibrinogen in the body (25). 
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Six different antithrombins have been described, however~ 
only three are known to playa significant role in the modulation 
of coagulation: ATI~ ATII and ATIII. Of these three, ATIII is 
the major thrombin inhibitor in plasma and the plasma cofactor 
through which heparin exerts its anticoagulant effect (26). Anti-
thrombin III is present in normal plasma at an average concentra-
tion of ~ 150 ~g/ml. When ATIII is added to thrombin, a slow de-
cline in thrombin activity is observed. Using purified protein it 
has been shown that thrombin combines with ATIII to form a 1:1 
stoichiometric complex (26). However, when heparin is added to a 
thrombin:ATIII mixture, thrombin neutralization is essentially 
instantaneous and the stoichiometry of the thrombin:ATIII complex 
is unchanged. The formation of the thrombin:ATIII complex is 
critically dependent upon the active serine center of thrombin. 
When this amino acid is blocked, all interactions between thrombin 
and antithrombin III are eliminated. Thrombin cleaves arginine-
glycine bonds in fibrinogen to form fibrin. Suspecting that 
thrombin binds to ATIII by a similar interaction, arginine on 
ATIII was blocked and it was found that thrombin could no longer 
complex with that ATIII (26). Similarily, in view of the high 
anionic character of heparin, it is likely that heparin would in-
teract with positively charged groups on proteins such as lysine 
residues. Chemical blocking of these residues on ATIII produced 
an ATIII which interacted normally with thrombin, resulting in a 
13 
slow decline in thrombin activity. However, this blocked ATIII 
does not bind heparin and when heparin was added to a mixture of 
thrombin and lysine blocked ATIII, inactivation of thrombin was 
indistinguishable from that without heparin (26). These findings 
have lead to the generally accepted hypothesis that heparin pre-
vents fibrinogen conversion to fibrin by first binding to ATIII to 
form a heparin:ATIII complex in which the thrombin binding site on 
the ATIII component of the complex is somehow more accessible to 
the active serine site on the protease enzyme. The heparin:ATIII 
complex then binds and neutralizes thrombin. This hypothesis is 
further supported by the fact heparin binding does induce confor-
mational changes in ATIII (27). 
If the hypothesis that an arginine binding site on ATIII in-
teracts with active serine sites is correct, then ATIII should 
bind and neutralize every active serine protease in the intrinsic 
coagulating pathway (factors Xlla, IXa, Xla, and Xa) and heparin 
should greatly accelerate these reactions. This was found to be 
the case for factor Xlla (28), factor IXa (29) and factor Xla 
(30). However, the affects of heparin on factor Xa inhibition 
have been observed to be quite different than with thrombin (31). 
Although ATIII does slowly inhibit factor Xa activity, substan-
tially less heparin is required to inhibit factor Xa in the pre-
sence of ATIII than to inhibit thrombin, and a linear relationship 
exists between the log of factor Xa activity and incubation time. 
With thrombin in the presence of ATIII, heparin inhibits the pro-
teolytic enzyme activity essentially instantaneously, suggesting 
14 
that heparin interacts via a different mechanism with factor Xa. 
The anticoagulant activities of different heparin molecular weight 
fractions supports the contention that heparin interacts via a 
different mechanism with factor Xa. Low molecular weight heparin 
has little effect on thrombin activity and a high antifactor Xa 
activity; whereas, high molecular weight heparin shows an opposite 
relationship (32). More recent studies have shown that ATIII 
possesses multiple heparin binding sites (33,34). Low molecular 
weight heparin can associate with ATIII to provide a 2:1 stoichio-
metric complex while high molecular weight heparin forms a 1:1 
stoichiometric complex with ATIII (33), suggesting a cooperative 
heparin binding model where two heparin binding sites on ATIII 
are in close proximity to each other. 
An increase in the rate of thrombin neutralization can be 
demonstrated at heparin concentrations as low as 0.02 units/ml 
(35). At this concentration, ATIII molecules outnumber heparin 
molecules by more than 100 to 1, indicating that heparin acts in 
a catalytic fashion with thrombin and ATIII. This is substanti-
ated by other findings. It has been proposed that heparin can be 
released for further ATIII binding after the thrombin:ATIII com-
plex has been formed (36), and it has been demonstrated that 
heparin weakly binds to ATIII after formation of the thrombin: 
ATIII complex as compared with the strong binding associated with 
noncomplexed ATIII (37). These results have been confirmed by 
others (38) where it was demonstrated that binding of thrombin to 
the heparin:ATIII complex results in the discharge of heparin, the 
thrombin:ATIII complexes having little ability to bind heparin, 
which can then bind noncomplexed ATIII with unchanged affinity. 
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More recent studies have shown that heparin contains both 
ATIII and thrombin binding sites (39,40,41) suggesting that throm-
bin is neutralized by binding to the heparin component of the 
heparin:ATIII complex; however, kinetic studies would indicate 
that this interaction is responsible for less than 2% of the 
thrombin neutralizing effect of the heparin:ATIII complex (42). 
Currently, three models exists for heparin interaction with 
ATIII and thrombin. The widely accepted model has been that hepa-
r;n first binds to ATIII, thereby potentiating binding of ATIII to 
thrombin. Heparin is then released from the ATIII:thrombin com-
plex for eventual binding to other free ATIII molecules. In the 
second model heparin also first binds to ATIII and thrombin in 
turn binds to the heparin component of the heparin:ATIII complex; 
however, this model cannot explan the catalytic role of heparin. 
The third model proposes the existence of a heparin:ATIII:thrombin 
complex where both ATIII and thrombin are initially bound to the 
heparin (40). Other studies have shown that heparin can prevent 
activation of factor X ;n the presence of factor VIlla, Ca+2, and 
phospholipid surfaces, in the absence of ATIII (43); casting some 
doubt on the validity of the heparin:ATIII interactions being the 
primary mechanism for the anticoagulant effect of heparin. It 
should be noted, however, that when heparin is administered to 
normal blood for prophylactic control of coagulation, very few 
activated proteolytic coagulation factors exist relative to the 
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great abundance of ATIII and one would expect the heparin to bind 
to free ATIII. Whatever mechanisms or combinations of mechanisms 
heparin does exert anticoagulant effects is the subject of great 
controversy. 
Heparin exerts other pharmacological functions, some in-
directly affecting its anticoagulant activity while others are 
totally removed from intrinsic coagulation interactions. Heparin 
is known to adversely affect platelet functions (44). Heparin 
has been shown to independently induce platelet aggregation and to 
potentiate platelet aggregation and release reactions caused by 
exogenous agents (45); high molecular weight heparin fraction 
being more deleterious to platelet functions than low molecular 
weight fractions (45). Once aggregated, platelets can release 
sUbstances which adversely effect hemostasis. Agents such as 
platelet factor 3 (PF3), and platelet factor 4 (PF4) can be re-
leased from platelets which can activate thrombin, in the case of 
PF3 (24), or bind to heparin and neutralize its anticoagulant 
activity in the case of PF4 (46). It has been shown that PF4 
binds to different sites on the heparin molecule than the ATIII 
binding site (47), further demonstrating the complexity of multi-
ple domains on the heparin molecule. 
Heparin shows many other pharmacological functions and has 
been reported to affect the activity of more than 50 enzymes (2). 
Heparin can trigger the release of lipoprotein lipases from endo-
thelium, adipose tissues and liver tissues (48) with consequent 
fatty acid level increases in plasma. Heparin initiates release 
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of histaminase from the intestinal mast cells (49), inhibits se-
cretion at aldosterone (50) with resultant lower adrenal function, 
and triggers the release of monosomes and polysomes from rough 
endoplasmic reticulum (51). 
In view of the complicated pharmacological effects associated 
with heparin and the danger of internal hemorrhaging from pro-
longed clotting times, an especially critical aspect to patients 
with hemophilic disorders and/or impaired hematopoietic function 
such as kidney dialysis patients, conventional heparin systemic 
administration can pose a high risk to the great number of indi-
viduals who routinely undergo treatment with blood contacting bio-
medical devices. To circumvent many of these undesired side re-
actions, many investigators have endeavored to incorporate hepa-
rin, and other anticoagulants, with the polymeric materials com-
posing the blood contacting surfaces of such devices. The incor-
poration of heparin with biomedical polymeric materials composing 
blood contacting surfaces can be divided into two catagories: 
materials providing a controlled release of heparin at the blood 
polymer interface, either by an ion exchange mechanism or by dif-
fusion through the polymer, and materials with surface immobilized 
heparin. In view of findings that heparin binds to vascular endo-
thelium (2,52) to provide an increased negative surface charge 
(2), and a high interfacial concentration of heparin at the blood/ 
vascular intima interface, this approach cannot only reduce side 
effects associated with systemic administration but also closely 
mimics the physiological behavior of heparin ~ vivo. A litera-
ture review of pertinent studies on heparin modification of bio-
medical materials follows. 
1.4 Controlled Release Materials 
1.4.1 Ionically Bound Heparin 
Polymers 
The pioneering work in heparin controlled release materials 
was accidentally initiated by Gott, et al. (53). At that time, 
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those investigators were evaluating numerous materials for throm-
bo-resistance by venous implantation and colloidal graphite gave 
the best results. These investigators first thought the thrombo-
resistance to be due to first; the extreme smoothness on a micro-
scopic level imparted to surfaces following graphite coating, and 
second; the chemically inert nature of carbon atoms composing the 
colloidal graphite. These materials were being sterilized by 
soaking in a Zepharin (R) (benzalkonium sulfate) solution. The 
surgeons then routinely soaked all implantable materials in a 
sterile heparin solution immediately prior to implantation. Dur-
ing the sterilization procedure, the hydrocarbon portion of the 
cationic surfactant was adsorbing to and penetrating into the 
graphite surface while the ionic portion was still associating 
with the aqueous phase. When these materials were placed in the 
heparin solution, heparin ionically exchanged with the sulfate 
anions to provide an ionically bound heparinized surface. When 
the heparinized materials were implanted, the heparin was slowly 
released from the graphite surface via an ion exchange mechanism 
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with anions of the circulating blood, thus providing a high in-
terfacial concentration of heparin at the blood/polymer interface. 
Further studies showed that these graphite-benzalkonium-heparin 
(GBH) surfaces retained significant quantities of heparin even 
after 3 months implantation in the venous system (54). 
A major disadvantage of the GBH surfaces is that the graphite 
can only be coated to rigid materials, any flexing would result in 
a desruption in the integrity of the graphite coating with possi-
ble "flaking-off ll of the GBH coating. To circumvent this problem, 
Leininger, et ale (55) endeavored to chemically modify numerous 
polymer surfaces by forming permanent surface associated quater-
nary ammonium groups, eliminating the need for prior adsorption of 
a cationic surfactant onto a hydrophobic surface such as graphite. 
Depending upon the polymer three surface treatments were used: 
(1) chloromethylation of styrene followed by quaternization with 
dimethyl aniline; (2) radiation grafting of vinyl pyridine to 
numerous polymers followed by quaternization with methyl iodine or 
benzylchloride; and (3) incorporation of quaternizable monomers 
such as vinyl pyridine into copolymers. After quaternization the 
surfaces were placed in a heparin solution and heparin was ioni-
cally bound to the ammonium groups. Following contact with fi-
brinogen, y-globulin and albumin solutions, Zeta potential mea-
surements indicated that the surfaces were progressively becoming 
less negatively charged, which the author attributed to plasma 
protein adsorption. From these studies the authors attributed the 
nonthrombogenicity of the heparinized surfaces to alterations in 
the plasma protein adsorption properties of the heparinized 
materials rather than to heparin release. 
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In an attempt to provide heparinized cellulose membranes 
that could be utilized in kidney dialysis applications, Merrill, 
et al. (56) ionically bound heparin to cellulose membranes via an 
ethylene imine intermediate. Various procedures were used to 
couple ethylene imine to the hydroxyl groups on cellulose. Of 
those procedures, pretreatment with ethylene oxide vapor, to con-
vert secondary cellulose hydroxyl groups into primarily hydroxyl 
groups, followed by reacting ethylene imine in toluene produced 
aminated surfaces which could then ionically bind heparin. Ethy-
lene imine reactions in aqueous solutions resulted in bulk amina-
tion of the cellulose, presumably due to increased swelling in 
water as opposed to toluene, which would ionically bind less hep-
arin per unit surface area. However, surfaces prepared by reac-
ting ethylene imine in 0.4 N Hel produced the greatest prolonga-
tions of whole blood clotting times. The authors attributed this 
finding to decreased cellulose crystallinity due to Hel dissolu-
tion of crystalline regions. Rather than attributing increased 
~ vitro clotting times to desorption of heparin, having deter-
mined that the ionically bound heparin was not washed off in the 
time limits involved in the ~ vitro clotting time tests, the 
authors attributed the increase clotting times to the adsorption 
of coagulation factors. Evidence to this hypothesis was provided 
by plasma adsorption studies where it was found that heparinized 
cellulose ethylene imine surfaces adsorbed substantially greater 
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quantities of plasma proteins than either cellulose or ethylene 
imine treated cellulose surfaces. Platelet interaction studies by 
Salzman, et al. (57) on the cellulose:ethylene imine:heparin sur-
faces demonstrated high degrees of platelet adhesion in vitro and 
with sufficiently high surface areas, significant thrombocytopenia 
in vivo which could be reduced by pretreatment with albumin. 
Prior adsorption of albumin is known to produce passive surfaces 
with respect to platelet interactions (58). The authors concluded 
that adverse platelet interactions were due to alternations in 
plasma protein adsorption characteristics of the heparinized sur-
faces, possible resulting in increased fibrinogen adsorption, a 
protein known to increase platelet adhesion to pretreated sur-
faces (59). 
Hersh, et ala (60) found that aminoorganosilane compounds 
could covalently bind to silica on glass surfaces previously 
cleaned with nitric acid. When y-aminopropyltriethoxysilane 
(APTES) was refluxed in toluene with cleaned glass, a stable sur-
face aminosilane was formed that could ionically bind heparin. 
This ionically bound heparin also appeared stably affixed to the 
surface and could resist fluid shear stresses as high as 104 
dynes/cm2 at 300 C for over 300 hours. In vitro whole blood clot-
ting times demonstrated a 10-fold increase in clotting times for 
the heparinized glass as opposed to untreated glass. 
Realizing the applicability of the APTES surface treatment 
with silica filled silicone rubbers, a material widely used in 
artificial organs, Merker, et al. (61) similarly prepared hepari-
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nized silicone rubber. 
Grode, et a1. (62) reported a simple procedure for ionical1y 
bonding heparin to silicone rubber. The silicone rubber was swol-
len in a 1:1 mixture of toluene and petroleum ether containing 
between 1-5% tridodecylmethylammonium chloride (TDMAC). The 
hydrocarbon portions of the quarternary amine adsorb onto and 
penetrates into the swollen silicone rubber, which was then vacuum 
dried. The TDMAC treated silicone rubber is then placed in a hep-
arin solution and heparin was ionically bound to the quaternary 
amine. The same TDMAC treatment could be applied to numerous bio-
medical materials including, polyurethane, polypropylene, MYla~R), 
polycarbonate, polyvinyl chloride and glass. The advantage of 
this procedure is that numerous materials could be heparinized 
without elaborate surface modification, the procedure is simple 
and all of these materials produced prolong clotting times. The 
disadvantages are: (L) TDMAC surfaces are unstable in plasma and 
TDMAC is released from the material and, (2) following release of 
heparin, TDMAC is directly exposed to the blood. These TDMAC sur-
faces in turn can adhere platelets. 
Yen and Rembaum (63) reported the preparation of an ionically 
bound heparin material where a quaternizable monomer is incorpo-
rated into the copolymer chain via a commerically available poly-
ether with terminal isocyanates. Subsequent quaternization with 
concentrated HCl resulted in the formation of cationic ammonium 
groups that could ionically bind between 7 to 16% by weight hepa-
rin, depending upon the abundance of the quatern;zable monomer in 
the copolymerization reaction. Blood could be stored in tubings 
coated with the heparinized elastomer for over 24 hours without 
clotting. 
23 
Tanzawa, et al. (64) described the preparation of a new 
hydrophilic heparinized polymer containing permanent quaternary 
ammonium groups in the copolymer formulation. A commercial graft 
copolymer composed of vinyl chloride, ethylene and vinylacetate 
was reacted with sodium N,N-diethyl-dithiocarbonate to introduce 
reactive dithiocarbamate groups. This dithiocarbamate derivatized 
hydrophobic copolymer was then copolymerized with methoxypoly-
ethyleneglycol methacrylate~ a hydrophilic monomer, and N,N-
dimethylaminoethyl methacrylate, a monomer with a quaternizable 
amine, by UV irradiation. The N,N-dimethylaminoethyl groups were 
subsequently quaternized by reaction with ethyl bromide to provide 
a final polymer containing hydrophobic, hydrophilic and cationic 
portions. The relative abundance of either component could be 
varied by varying monomer feed compositions to provide a wide 
range of swelling characteristics. Catheters, polymer films, 
tubings, etc. could be coated with the above cationic polymer by 
solvent casting from a mixture of cyclohexanone and dimethyl-
formamide containing 2-3% of the cationic polymer. After casting~ 
the polymer coatings were dried at 700 C for 5 hours and the re-
maining solvent was extracted in methanol, which was subsequently 
evaporated. Finally, these materials were soaked in a 2% sodium 
heparin solution for 1-3 days to ionically bind heparin to the 
quaternary ammonium groups. The relative abundance of hydrophobic 
24 
and hydrophilic groups, including both methoxypolyethylenegylcol 
methacrylate and the cationic methacrylate as hydrophilic groups, 
as determined by elemental analysis and by bromide titrations of 
ionic nitrogen atoms, ranged from 79%:21% (hydrophobic:hydrophi-
lic) to 68%:32% with corresponding equilibrium hydrations of 
final heparinized polymers ranging from 12% to 44% water. These 
materials could bind as much as 19% by weight heparin, thus pro-
viding a large depot of heparin allowing high release rates over 
extended periods of time. Extensive in vitro and in vivo evalua-
tions of these heparinized materials (64,65,66,67) have estab-
lished a minimum heparin released rate of 4 X 10-2 ~g/cm2/min as 
a critical parameter for nonthrombogen;city. This critical re-
lease rate could be provided for months ~ vivo by heparinized 
polymers with 15% by weight heparin and a hydrophobic:hydrophilic 
ratio providing 30% by weight equilibrium sweiling in water. 
Until the development of this heparin reservoir controlled 
release polymer, all other polymers previously sited provide hep-
arin release only of surface bound heparin and the release kine-
tics were solely controlled by the ion exchange process. With the 
polymers developed by Tanzawa, et al. (64), heparin is first re-
leased from its cationic binding site by an ion exchange mechanism 
and then must diffuse through the polymer matrix to the surface 
where it is released into the blood or aqueous phase. With these 
polymers, the diffusion of heparin becomes the rate limiting step 
and therefore controls release kinetics. This rate limiting dif-
fusion can then be controlled by the hydrophobic/hydrophilic ratio 
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of the polymer composition, providing an exquisite means for con-
trolling heparin release. 
Holland, et al. (68) have recently reported a convenient 
method for ionically binding heparin to hemodialysis membranes. 
By dissolving 5% diethylaminoethyl cellulose with 95% cellulose in 
appropriate solvents, cellulosic membranes are readily formed that 
contain cationic groups capable of ionically binding heparin. 
Heparin is released from these membranes and coagulation in con-
tacting blood is controlled; however, platelets adversely interact 
with the membranes and platelet levels significantly decrease, 
compared to control cellulose membranes, with increased contact 
time. 
A chronological summary of ionically bound, controlled re-
lease heparin polymers is presented in Table I. 
1 .4.2 Dispersed Heparin Polymers 
A second means to provide heparinized polymers is to simply 
blend heparin throughout the polymer matrix, eliminating the need 
for cationic groups that may either leach off or remain as a per-
manent component of the polymer composition. By avoiding cationic 
groups, which can adversely affect platelets, improved ~ vivo 
blood compatibility can be expected. 
Hufnagel, et al. (69) were first to incorporate heparin into 
either silicone rubber or a combination of silicone rubber plus 
colloidal graphite. Patches approximately 7 mm in diameter and 3 













































































































































































































































































































































































































































































































































































































































































































































































rubber plus col1odia1 graphite as control materials. Similar 
patches were prepared with heparin incorporated into silicone rub-
ber and silicone rubber plus colloidal graphite ("Hepacone" and 
IIHepacone-G" respectively). When these materials were sutured 
onto the right atrial wall of mongrel dogs, both control materials 
were completely thrombosed within two hours while the Hepacone 
and Hepacone-G materials showed no thrombus formation even after 
6 months. 
Salyer and Weesner (70) blended heparin into eposy resins. 
Polymers containing 3 and 7 parts heparin per 100 parts of resin 
showed excellent nonthrombogenicity over a two week period of 
vascular implantation. These materials were shown to have greater 
initial plasma protein adsorption, when implanted in the venous 
system of dogs, than identical materials without heparin. How-
ever, after two weeks, the unheparinized materials were completely 
covered with thrombus while the heparin incorporated materials 
were clot free. These findings indicate that the incorporation of 
heparin into the polymeric materials influenced the adsorption of 
a benign protein iayer; whereas without heparin, the material ad-
sorbed proteins which presumably adversely interacted with plate-
lets. 
Although these authors initially thought the nonthrombogeni-
city of these materials was due to the slow leaching out of hepa-
rin into the blood phase, later studies by Salyer, et al. (71) 
showed that when heparin was combined with epoxy resin and ure-
thane monomers, polymerization resulted in covalent incorporation 
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of heparin into the copolymer composition to form either poly-
(heparin-ether) or poly(heparin-urethane) copolymers and heparin 
was not leaching out. In this study, the authors also investi-
gated heparin ionically bound to permanent quaternary ammonium 
groups in the polymer composition. Epoxy and urethane polymers 
with chemically incorporated heparin demonstrated vastly in-
creased whole blood clotting times relative to controlled poly-
mers. Furthermore, these materials could be thoroughly washed 
and exposed to fresh blood for 30 minute periods, repeating this 
process for up to 26 times, and no clotting was observed. Im-
plantation into the venous system of dogs showed no thrombus for-
mation for up to 6 months. 
A novel approach to the controlled release of heparin from 
polymer matrices was provided by Ebert, et al. (72). As previous-
ly stated, heparin can adversely interact with platelets, re-
sulting in aggregation and potentiation of aggregation and re-
lease reactions caused by exogenous agents. Prostaglandins (PGE1, 
PGI 2, PGD2) are agents known to prevent platelet aggregation and 
degranulation by stimulating membrane bound adenyl cyclase, re-
sulting in increase intracellular c-AMP levels (73,74,75). By 
combining both heparin and prostaglandin into controlled release 
polymer matrices, both intrinsic coagulation and adverse platelet 
interactions could be controlled. When heparin and PGE l were 
simultaneously combined with dissolved poly-hydroxyethyl methacry-
late, polymers were formed where heparin and PGE l were released 
over approximately a 10 hour period. Bioassays of both heparin 
and PGE l showed that neither agent had decreased biological 
activity resulting from polymer fabrication techniques. 
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These materials inhibited blood coagulation and platelet ad-
hesion via separate biological mechanisms; however, due to the 
quick release rate, they would not be applicable to long term ap-
plications. A summary of physically dispersed, controlled re-
lease heparin polymers is presented in Table II. 
1.5 Covalently Immobilized Heparin 
Materials 
A disadvantage with the ionically bound and physically dis-
persed heparin/polymer systems is that heparin is continually de-
pleted with time, thereby limiting the effective anticoagulant 
duration of such materials. Numerous investigators have covalent-
ly bound heparin to polymer surfaces to provide long term hepa-
rinized materials. 
Grode, et ale (76) in addition to reporting progress on TDMAC 
ionically heparinized materials, reported the covalent coupling of 
heparin to APTES treated silicone rubber via a heparin/cyanuric 
chloride adduct. The authors also reported a procedure for radia-
tion grafting polystyrene to various polymeric materials. The re-
sultant polystyrene surfaces were then chloromethylated and sub-
sequently treated with an ammonia/alcohol solution to form benzyl-
amine groups. These polystyrene/benzylamine surfaces were then 
heparinized via the heparin/cyanuric chloride adduct. Heparin at-
tachment was stable, even in 4N NaCl, and the authors report that 







































































































































































































































































































































































































































































































clotting times. ~ vivo venous implantation tests (77) showed 
that cyanuric chloride/heparin adduct covalently coupled to APTES 
treated silicone rubber produced materials that prevented throm-
bus formation for up to 6 months. 
Merrill, et al. (78) covalently coupled heparin to polyvinyl 
alcohol via glutaraldehyde crosslinking in the presence of an 
acid catalyst through hydroxyl groups on heparin and polyvinyl 
alcohol. Using 35S-labeled heparin covalently coupled to poly-
vinyl alcohol, numerous clotting tests were conducted including 
thrombin time, partial thromboplastin time, activated partial 
thromboplastic time, prothrombin time and whole blood clotting 
time. In all cases, clotting times were increased following plas-
ma or whole blood, depending upon the test, exposure with the co-
valently heparinized material. Sulfur-35 analyses of resultant 
plasmas showed no heparin to be present, eliminating the possi-
bility that prolonged clotting times were due to heparin release. 
Pretreatment of the heparinized materials with albumin resulted in 
thrombin times paralleling control material. This lead the 
authors to the conclusion that specific coagulation factors were 
interacting with the immobilized heparin, resulting in coagulation 
factor deficient plasma, thereby producing prolonged clotting 
times. Pretreatment with albumin therefore covered heparin bind-
ing sites for coagulation factors. Coagulation factor assays on 
plasma exposed for 15 minutes to the heparinized material demon-
strated up to a 59% decrease in factor XI, a 44% decrease in 
factor IX and a 29% decrease in factor V. 
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When platelet rich plasma was exposed to heparinized poly-
vinyl alcohol, for 20 minutes, platelet levels decreased 29.8%; 
however, since untreated polyvinyl alcohol and glutaraldehyde 
treated polyvinyl alcohol materials were not evaluated, conclu-
sions regarding platelet interaction with the immobilized heparin 
cannot be made. 
Lagergren and Eriksson (79) first reported the preparation of 
a crosslinked heparin monolayer surface. By first adsorbing a 
cationic surfactant, surfactants with 16-18 carbon atoms worked 
best, onto a polypropylene surface, cationic surface groups were 
introduced that could bind heparin as with the numerous ionically 
bound heparin polymers. The heparin molecules ionically bound to 
the cationic surface sites were then crosslinked with glutaralde-
hyde to provide a covalently stabilized heparin monolayer. When 
blood was exposed to such surfaces no clotting was observed even 
after 3 hours of contact; however, when the same blood was then 
subsequently placed in contact with glass, clotting was observed 
in 9 minutes. 
Arteriovenous shunts were prepared with 3 mm ID polypropylene 
tubing with the crosslinked heparin monolayer, control shunts con-
sisted of untreated polypropylene. When placed between the 
femoral artery and vein of mongrel dogs, the heparin monolayer 
shunts remained open for over 12 hours while the untreated poly-
propylene shunts completely thrombosed within 7-12 minutes. 
This group has since published several papers on the prepara-
tion of heparin crosslinked monolayers with various substrate 
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materials and their evaluations. In general, the heparin mono-
layer is stabled, approximately 3% of the total affixed heparin is 
released over an initial 10 hour period and essentially no release 
occurs thereafter (80). Blood exposed to such surfaces demon-
strates variable prolonged clotting times depending upon the de-
gree of g1utaraldehyde crosslinking. This has been described by 
Larsson, et al. (81) to be related to the ability of the affixed 
heparin to migrate from the surface and become incorporated into 
the surface adsorbed plasma proteins. By use of Auger spectro-
scopy, Eriksson, et al. (82) have shown sulfur (i.e., heparin) to 
be present on the surface of the adsorbed protein layer which they 
take as evidence for the above hypothesis. Finally, platelet 
compatibility is dramatically improved relative to untreated con-
trol materials (83). 
Schmer (84) covalently coupled heparin to agarose by three 
methods: (1) direct coupling of heparin to cyanogen bromide acti-
vated agarose; (2) coupling of heparin to putrescine on putrescine 
derivatized agarose via thiophosgene and; (3) covalent coupling of 
heparin to amine groups on s-amino caproyl of s-amino caproyl 
derivatized agarose via a water soluble carbodiimide. The first 
method represents essentially direct coupling to the surface, the 
imidocarbonate group formed via the cyanogen bromide activated 
groups being rather small. The second and third methods interpose 
a spacer arm between the surface and the affixed heparin. Not 
only were greater quanities of heparin immobilized onto the spacer 
arm derivatized agaroses, but the ability of the immobilized hep-
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arin to bind ATIII was also increased. No differences were dis-
tinguishable in both coupling yields and ATIII binding for heparin 
coupled via the thiophosgene reaction or the carbodiimide reac-
tion. In both reactions, heparin was coupled via primary amine 
groups on heparin to the appropriate spacer arm. 
Labarre, et al. (85) described the preparation of a heparin-
methyl methacrylate copolymer. The reaction between hydroxyl 
groups on poly alcohols (i .e., heparin) with cerium (IV) salts in 
acidic aqueous solutions is known to produce free radicals capable 
of polymerizing vinyl monomers. By dissolving heparin in a 0.25 M 
nitric acid solution, to which an ammonium cerium (IV) nitrate and 
methyl methacrylic monomer are serially added, an insoluble 
heparin-methyl methacrylate copolymer is formed. Due to the nu-
merous hydroxyl groups present on a heparin molecule, this co-
polymer is most likely a block copolymer consisting of a heparin 
core from which poly-methyl methacrylate chains extend. These 
heparin-MMA copolymers show a dose related anticoagulant activity 
verified by both plasma recalcification time and thrombin time 
assays. Later studies (86) showed these increased clotting times 
were due, in part, to noncovalently bonded heparin released from 
the insoluble heparin-MMA copolymer. Pretreatment of the copoly-
mer with a sodium citrate solution removed that nonbound heparin, 
presumably by chelating cerium (III) ions formed during the co-
polymerization reaction, to which heparin was ionically binding. 
These washed copolymers also prolong thrombin times, both when 
evaluating plasma-copolymer suspensions and supernatants obtained 
by centrifugation of plasma-copolymer suspensions, in a dose re-
lated manner. 
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Danishefsky and Tzeng (87) reported the preparation of a 
heparin-agarose polymer, where heparin was linked via an amino-
ethyl spacer arm. Aminoethyl agarose was mixed with a heparin 
solution, the pH was lowered to 4.75 and a water soluble carbodi-
imide was added to form an amide bond between heparin carboxylic 
groups and amine groups on the derivatized agarose. The reaction 
took place initially for 6 hours at room temperature, followed by 
approximately 18 hours at 40C. The heparinized gels were washed 
with concentrated NaCl and stored several months. No leaching of 
heparin was observed during the storage. One ml columns were pre-
pared with the heparinized gel and citrated plasma was eluted 
through each column, sequential fractions were collected. The 
first fractions did not clot upon recalcification for over one 
hour and activated partial thromboplastin times were in excess of 
25 minutes. Subsequent fractions clotted upon recalcification 
within 15 minutes, while final fractions showed recalcification 
times equivalent to untreated plasma. When the columns were 
thoroughly washed with 4 M NaCl and reequilibrated with 0.9% NaCl, 
subsequent addition of plasma again produce plasma fractions with 
prolonged clotting times, indicating saturation of heparin binding 
sites for coagulation factors. Washing the plasma treated columns 
with 0.4 M and 1.2 M NaCl eluted fractions containing factors IX 
and XI respectively, as determined by the addition of 0.4 M NaCl 
and 1.2 M NaCl elutants to factor IX and factor XI deficient 
plasmas. Additional assays for ATIII revealed that the immobi-
lized heparin was also binding ATIII, only to a smaller extent 
than factors IX and XI. 
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Goosen and Sefton (88) reported the synthesis of a heparin-
ized styrene-butadiene-styrene (SBS) elastomer. The double bonds 
of the butadiene components of the SBS rubber were first hydroxy-
lated by reaction with peracetic acid. By controlling reacting 
conditions the process could be limited to the SBS polymer sur-
face, thereby preserving the elastomeric bulk properties of the 
material. After cleaning the surfaces by either giow discharging 
or ultrasonic cleaning, the hydroxylated SBS films were dipped in 
a solution containing polyvinyl alcohol, formaldehyde, glutaral-
dehyde, glycerol, magnesium chloride, sodium heparin and water. A 
resultant lamination occurs where the hydroxyl groups on the SBS 
surface bond via acetal bridges to the hydroxyl groups of heparin. 
This procedure results in a tightly adhering PVA laminated SBS 
rubber with heparin covalently immobilized to the PVA surface. 
When plasma was exposed to these surfaces, partial thromboplastin 
times were greatly elevated, eluted 35S-heparin was not detectable 
in the plasma. Similarily, A-V silastic shunts coated with the 
heparinized SBS material remained nonthrombosed for extended dura-
tions relative to nonheparinized SBS coated shunts. When whole 
blood was incubated inside heparinized shunts, no clots were ob-
served after 45 minutes. Placing that same blood in contact with 
glass resulted in subsequent clotting within 5 minutes. Platelet 
adhesion testing, however, revealed significantly increased adhe-
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sion for heparinized materials relative to unheparinized controls. 
Muria, et al. (89) have immobilized heparin to a variety of 
cyanogen bromide activated surfaces including sepharose, poly-
hydroxyethyl methacrylate (P-HEMA) and polyvinyl alcohol. Heparin 
immobilized on sepharose or P-HEMA greatly prolonged plasma recal-
cification times while heparin immobilized on PVA did not greatly 
effect plasma recalcification times. Thrombin is instantaneously 
neutralized in the presence of soluble heparin and ATlll; however, 
thrombin neutralization by immobilized heparin was indistinguish-
able in the presence or absence of ATlll. This finding would in-
dicate that under these immobilization conditions, utilizing amine 
groups on heparin, immobilized heparin was not able to interact 
with ATlll in the same manner as it does with soluble heparin. 
This could also be interpretated as evidence that heparin 
acts by first binding to thrombin, potentiating ATTll binding to a 
heparin/thrombin complex. Recent studies by Goosen and Sefton 
(90) using polyvinyl alcohol immobilized heparin, prepared accord-
ing to the methods of Merrill, et al. (78), demonstrated that im-
mobilized heparin neutralized thrombin by first binding thrombin 
to form a heparin/thrombin complex that further binds ATllI. 
With both of these systems, heparin is immobilized in close 
proximity to the polymer surface. Schmer (84) demonstrated that 
heparin immobilized by a cyanogen bromide reaction, identical to 
the methods of Muira (89), did not bind ATlll as effectively as 
heparin immobilized via a spacer arm separating the affixed hep-
arin from the surface. A poss~[bil;ty that neither Muira or Goosen 
have addressed, is that their immobilized heparin systems do not 
allow interactions between immobilized heparin and ATIII similar 
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to interaction between soluble heparin and ATIII. The ATIII bind-
ing sites on the immobilized heparin may not have been accessible 
to ATIII. 
A summary of immobilized heparin polymers is presented in 
Table III. 
1.6 Hypothesis for Immobilized 
Heparin Activity 
When blood contacts an immobilized heparin surface proteins 
are adsorbed. If those adsorbed proteins included coagulation 
factors, ~ vitro clotting times may be increased. In any event, 
the nature of those adsorbed proteins can influence platelet in-
teractions with the surface during in vivo usage and the presence 
of the highly anionic heparin would be expected to possibly alter 
the nature of those adsorbed proteins relative to the initial con-
trol surface. 
Previous work with immobilized heparin surfaces has shown 
that these materials adsorb coagulation factors and thereby pro-
long ~ vitro clotting times; however, does the heparin immobi-
lized onto these material interact similar to soluble heparin or 
are the prolonged in vitro clotting times simply the manifestation 
of plasma protein interactions with a negatively charged surface? 
Past investigators have immobilized heparin via several func-
tional groups on the heparin molecule (amine~ hydroxyl and car-







































































































































































































































































































































































































































































































































































































































































































































































lished the effects of derivatizing those groups on the heparin 
anticoagulant activity. It is entirely possible that blocking 
those groups in reactions similar to the immobilization reactions 
could result in the loss of anticoagulant activity and one would 
then conclude that heparin immobilized via those groups would also 
not be active. 
Another unanswered question lies in the protein adsorption/ 
platelet interaction phenomena. Do platelets actually contact 
immobilized heparin or do the adsorbed plasma proteins mask the 
heparinized surface? In the first case, immobilized heparin could 
adversely affect platelets similar to soluble heparin interactions 
with platelets, while in the latter case, the nature of the ad-
sorbed plasma proteins would dictate platelet interactions and im-
mobilized heparin would be indirectly affecting platelets by in-
fluencing the nature of the adsorbed plasma proteins. 
As previously stated, soluble heparin inhibits thrombin ac-
tivity and the activity of other coagulation~ factors presumably 
via antithrombin III. The majority of past work would indicate 
that immobilized heparin does not interact with ATIII as does 
soluble heparin, thrombin neutralization by immobilized heparin 
being indistinguishable in the presence or absence of ATIII being 
one example (89). However, Schmer, et al. (84) have shown that 
immobilized heparin can better interact with ATIII if the heparin 
was immobilized via a spacer arm. 
Work in this dissertation is divided into four major cate-
gories: 
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(1) Heparin derivatization to determine changes in antico-
agulant potency associated with the covalent modification of 
specific functional groups, thereby determining which functional 
groups should participate in immobilization reactions. 
(2) The effects of spacer arm length on immobilized heparin 
anticoagulant activity. 
(3) Platelet interactions with immobilized heparin. 
(4) Evaluation of adsorbed protein surface interactions with 
heparin immobilized surfaces. 
ECCLES lil:P'l TN SCUJ~CES liBRARY 
CHAPTER 2 
METHODS 
2.1 Functional Group 
Derivatizations 
2.1.1 Amine Group Derivatization 
Free amine groups on porcine intestinal sodium heparin (Sigma 
Chemical Company) were blocked with acetic anhydride (91) by the 
following procedures. Three and one quarter grams of sodium hep-
arin, activity - 153 USP units/mg, were dissolved in 300 ml of dis-
tilled water (pH - 6.29) to which 1.63 grams of NaHCO~ were added 
~ 
(pH - 8.40). A USP unit of activity is defined as a plasma hepa-
rin activity producing 50% clotting in citrated sheep plasma one 
hour after the addition of excess calcium chloride. This solution 
was cooled to OoC in an ice bath. Reagent grade acetic anhydride 
(American Scientific and Chemical Company) was added to acetone, 
o 
previously distilled and collected over 3A molecular seives (MCB 
Manufacturing Chemists, Inc.) to remove water; a total of 6.54 ml 
acetic anhydride was added to 32.7 ml acetone. This acetic anhy-
dride solution was added drop wise over 40 minutes to the OoC 
heparin solution while constantly stirring and maintaining the pH 
between 8.0 and 8.4 by the addition of 1 M Na 2C03. After the ad-
dition of the acetic anhydride, the reaction was brought to room 
temperature for 2.5 hours while maintaining the pH between 8.0 and 
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8.4 with the addition of 1 M Na 2C03, The reaction contents were 
then dialyzed at 20 C in 2000 MW cut off dialysis tubes (Spectrum 
Chemical Company) with distilled water for 3 days; changing the 
dialysate, total volume 5 liters, twice a day_ After the final 
dialysis, the heparin solution was first concentrated by roto-
evapor;zation at 35-400C and freeze dried, 
2.1.2 Carboxylic Group 
Derivatization 
Since crosslinking between free amine groups on heparin with 
activated carboxylic groups on heparin formed during the carboxy-
lic group derivatization reactions was a concern, N-acetylated 
heparin, which was prepared as described in the previous section, 
was used ;n all carboxylic group derivatization studies. Two 
grams of N-acetylated heparin and 2.0 ml of n-butylamine were 
dissolved in 40 ml of distilled water and the reaction vessel was 
placed in a cold room at approximately 2-40 C. The pH was adjusted 
to 4.75 with 1 M HCl and a total of 0.8 grams of l-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) (Sigma 
Chemical Company) was added to the heparin/n-butylamine solution 
in approximately 10 to 20 mg portions over a 6 hour period while 
constantly stirring. 
Periodic samples were withdrawn from the reaction vessel dur-
ing the 6 hour period and dialyzed at 20 C with 2000 MW cut off 
dialysis tubes for 2 days in 1 M NaCl, changing the 5 liter dialy-
sate volume twice each day. Finally, the samples were dialyzed 
with distilled water for 1 day, changing the dialysate twice. The 
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samples were concentrated by roto-evaporization at 35-40oC and 
freeze dried. 
In a separate reaction, 0.5 grams of N-acety1ated heparin 
and gram 2-aminoethy1 hydrogen sulfate (Aldrich Chemical Com-
pany) were dissolved in 10 m1 of distilled water and the reaction 
was placed in the cold room at approximately 2-4oC. The pH was 
adjusted to 4.75 with 1 M HC1 and a total of 0.2 grams of EDC 
were added in approximately 10 to 20 mg portions over a 4 hour 
period while constantly stirring. The reaction contents were then 
dialyzed in 2000 MW cut off dialysis tubes with 1 M NaCl for 2 
days, changing the 5 liter dialysate volume twice a day, followed 
by 1 day of dialyses with distilled water, changing the dialysate 
twice. The sample was then concentrated by roto-evaporatization 
at 35-40oC and freeze dried. The carbodiimide reaction scheme 
(92) is presented in Figure 4. 
2.1.3 Hydroxyl Group Derivatization 
Epichlorohydrin Reactions 
As with the carboxylic group derivatization reactions, all 
hydroxyl group derivatization reactions were conducted with N-
acetylated heparin to prevent intra- and intermolecular cross-
linking. One half gram of N-acetylated heparin was first dis-
solved in 1.0 M Na 2C03 and then placed in a 40
0C water bath. One 
milliliter of epichlorohydrin (Aldrich Chemical Company) and 
either 1 ml of n-butylamine (Aldrich Chemical Company) or 1 gram 
of glycine (Aldrich Chemical Company) or 2-aminoethyl hydrogen 


































































































































































































emulsion being constantly stirred. After 5 hours of reaction 
time at 400C, the reaction samples were transferred to dialysis 
tubing and dialyzed against 1 M NaC1 for 2 days, changing the 5 
liter dialysate twice a day, followed by day dialysis against 
distilled water, which was also changed twice. The hydroxyl 
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group derivatized heparin samples were concentrated by roto-
evaporization and finally freeze dried. The epichlorohydrin re-
action scheme is shown in Figure 5. 
2.1.4 Hydroxyl Group Derivatization 
Oivinylsulfone Reactions 
One half gram of N-acety1ated heparin was dissolved in 10 ml 
of 1.0 M Na 2C03 solution. One milliliter of divinylsulfone 
(Aldrich Chemical Company) and either 1 ml of n-butylamine or 
gram of either glycine or 2-aminoethy1 hydrogen sulfate were 
added to the heparin solution to form an emulsion which was con-
stantly stirred at room temperature for 3 hours. The reaction 
contents were then dialyzed in 2000 MW cut of dialysis tubes for 
2 days in 1 M NaCl followed by 1 day dialysis in distilled water; 
the 5 liter dialysate volume, either 1 M NaCl or distilled water, 
was changed twice each day. After dialysis, the samples were con-
centrated by roto-evaporization and freeze dried. The divinyl-



























































































































































































































































2.2 POlymer Substrate Preparation 
for Heparin Immobilization 
2.2.1 Oiaminoalkane-Agaroses 
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Oiaminoalkane-agaroses (Sigma Chemical Company) were washed 
with pH 7.4 phosphate buffered saline (PBS) and used without fur-
ther treatment. These materials were used in ~ vitro coagulation 
studies due to the high surface areas obtained for that bead dia-
meter (~ 100 ~m). The diaminoalkane derivatized agaroses were as 
follows: 1,2 diaminoethane-agarose, 1,4 diaminobutane-agarose, 
1,8 diaminooctane-agarose, 1,10 diaminodecane-agarose and 1,12 
diaminododecane-agarose. 
2.2.2 Oiaminoalkane Coupling to 
Sepharose 6-MB Beads 
All platelet interaction studies were conducted on Sepharose 
6-MB (Pharmacia Fine Chemicals, Inc.) derivatized beads. These 
beads provide greater surface areas for platelet interaction stu-
dies compared to flat surfaces; however, these beads are sub-
stantially larger (mean diameter ~ 400 ~m) than the agarose beads 
used in ~ vitro coagulation testing (~ 100 ~m mean diameter). The 
Sepharose 6-MB, because of their larger size, are more suited to 
column type platelet interaction studies than small beads which 
provide interstitial gaps too small for blood cells to pass 
through. Oiaminoalkane derivatized Sepharose 6-MB beads were pre-
pared with CNBr activated Sepharose 6-MB (purchased as CNBr acti-
vated beads). These beads were obtained in a dehydrated state 
containing agents to preserve the pore structure and bead shaped 
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following dehydration. Ten grams of the dehydrated Sepharose 6-
MB beads were first hydrated in 2 liters of 0.02 M HCl for 30 min-
utes to hydrate the beads and extract the above additives as per 
the manufacture's recommendation. If this first step is not fol-
lowed, subsequent coupling reactions are greatly diminished. The 
0.02 M HCl hydrated beads were then suction dried on a sintered 
glass funnel and rehydrated in 0.5 M Na2C03 for 2 hours, the solu-
tion to be used in subsequent coupling reactions. The beads were 
then suction dried again and divided into two portions which were 
added to either 3.0 grams of diaminobutane dissolved in 100 ml of 
0.5 M Na 2C03 or 3.0 grams of diaminododecane dispersed in 100 ml 
of 0.5 M Na 2C03, due to the low aqueous solubility of diaminodo-
decano, in closed vessels. The vessels were rotated at approxi-
mately 1 revolution per second for 4 hours at room temperature 
(stirring will destroy the bead structure), and then stored at 20C 
for 24 hours. The diaminoalkane derivatized beads were then re-
peatedly washed with pH 7.4 phosphate buffered isotonic saline and 
suctioned dried with a sintered glass funnel. The beads, still 
hydrated, were then placed in 100 ml of 2 M ethanolamine in 0.5 M 
Na 2C03 solution for 24 hours at 2
0C to block any possible remain-
ing CNBr activated sites. The beads were then again repeatedly 
washed with pH 7.4 phosphate buffered isotonic saline and stored 
at 20C for 1 month in the buffered saline solution. 
2.2.3 Diaminoalkane Coupling to 
eel lulose sheets 
CuproPhaJR) a commercially available regenerated cellulose, 
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was obtained from a Gambro lundia majo~R) hemodialyzer (Gambro 
Inc.) and was the polymer substrate used for all IIflat sheetll im-
mobilized heparin evaluations. To remove glycerol, Cuprophan was 
first washed by soxhlet extraction with double distilled water for 
24 hours. The Cuprophan was then cyanogen bromide activated by 
reacting a total of 250 cm2~ divided into ~ 1 X 2 cm2 pieces, with 
10 gms of CNBr (Aldrich Chemical Company) dissolved in 400 ml of 
0.5 M Na 2C03 at a pH of 11.3 for 10 minutes. The CNBr activated 
cellulose sheets were then thorough1y washed with distilled water 
and divided into portions which were then reacted with either 3.0 
grams of diaminobutane (Aldrich Chemical Company) in 100 ml of 
0.5 M Na 2C03 or with 3.0 grams of diaminododecane (Aldrich Chemi-
cal Company) dispersed in 100 ml of 0.5 M Na 2C03, due to the low 
aqueous solubility of the diaminododecane~ for 4 hours at 220C 
followed by 24 hours at 2oC. 
The above diaminobutane and diaminododecane derivatized cel-
lulose sheets were extensively washed with pH 7.4 phosphate buf-
fer isotonic saline and possible remaining CNBr activated sites 
were blocked by placing the diaminoalkane derivatized sheets in 
100 ml of 2 M ethanolamine in 0.5 M Na2C03 solution at 2
0C for 24 
hours. The diaminobutane and diaminododecane derivatized cellu-
10se sheets were then extensively washed again in pH 7.4 phosphate 
buffered isotonic saline and stored 1 month in pH 7.4 PBS at 2oC. 
The CNBr activation and diaminoalkane coupling reaction schemes 



















2.3 Quantitation of Degrees of 
Diaminoa1kane Coupling to 
Polymer Substrates 
2.3.1 Preparation of l4C-Sodium 
Acetate 
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Carbon-14 labeled sodium acetate (New England Nuclear) was 
mixed with a solution of cold anhydrous sodium acetate (Aldrich 
Chemical Company) in doubled distilled water and freeze dried. 
Weighed samples of the resultant diluted l4C-sodium acetate were 
dissolved in water, portions of which were then dissolved in liq-
uid scintillation fluid and counted for carbon-14. The above 
14C-sodium acetate had a specific activity of 202,191 ~ 1,236 dpm/ 
mg. Carbon-14 levels in blank scintillation fluid ranged from 10-
20 cpm, 15 cpm was therefore subtracted from all C-14 samples and 
respective dpms were recalculated. 
2.3.2 Determination of 
Diaminoalkane Coupling to 
Agarose Beads 
The degrees of diaminoalkane coupling to agarose gels was 
conducted by the manufacturer and was supplied with each gel. 
2.3.3 Determination of 
Diaminoalkane Coupling to 
Sepharose 6-MB - Sodium 
Acetate Coupling 
The methods for coupling 14c acetate to the diaminoalkane 
derivatized Sepharose 6-MB were analogous to the methods in Section 
2.1.2 above. Known packed gel volumes of hydrated diaminobutane 
and diaminododecane derivatized Sepharose 6-MB (~ 2 cc), after 
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one month storage and subsequent washing, were added to a 20 ml 
solution containing 190 mg l4C-sodium acetate plus 822 mg of EDC, 
approximate molar ratio 1:2. The pH was adjusted to 4.75 and the 
reaction proceeded at 2-4oC for 24 hours. The gels were then re-
peatedly washed with pH 7.4 buffered saline until C-14 was not 
detected above background in the wash solutions. The l4C-acetate 
coupled beads were then vacuum dried. 
Three milliliters of concentrated sulfuric acid was then 
added to hydrolytically cleave the glycosidic bonds and 3.0 ml of 
ethanol was then added to each solution. Two hundred and fifty 
microliters of each solution was then counted for carbon-14. 
Each acid dissolved polymer was counted in triplicate. For de-
termining the specific activity of the immobilized 14C-acetate 
the specific activity of the sodium acetate had to be adjusted to 
include only the acetate portion. The specific activity of the 
acetic acid coupled to the diaminoalkane derivatized Sepharose 
6-MB was then 271,798 ~ 1,662 dpm/mg. 
2.3.4 Coupling of l4C-Sodium 
Acetate to Diaminoalkane 
Cellulose Sheets 
The degree of diaminobutane and diaminododecane coupling to 
the CNBr activated cellulose sheets was determined by coupling 
l4C-sodium acetate to the terminal primary amines of the deriva-
tized cellulose with EDC as described above. Known surfaces 
areas (~ 30 cm2) of hydrated diaminobutane and diaminododecane 
derivatized cellulose sheets, after one month storage, were added 
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to a 20 ml solution containing 190 mg l4C-sodium acetate plus 822 
mg of EDC in distilled water. The pH was lowered to 4.75 and the 
reaction was conducted for 24 hours at 2-40C. The reaction 
scheme is analogous to that depicted in Figure 4. After 24 
hours reaction time, the l4C-acetate coupled diaminoalkane deri-
vatized cellulose sheets were repeatedly washed with pH 7.4 phos-
phate buffered saline until no carbon-14 was detected above back-
ground in the wash solutions. The labeled cellulose sheets were 
then vacuum dried. 
Three milliliters of concentrated sulfuric acid was then 
added to each labeled cellulose sheet to hydrolytically cleave 
the glycosidic bonds, 3.0 ml of ethanol was then added to each 
resultant solution. Two hundred and fifty microliters of each 
solution was then counted for carbon-14. Each acid dissolved 
cellulose was counted in triplicate. 
2.4 Heparin Immobilization to 
Polymer Substrates 
2.4.1 Heparin Immobilization to 
Diaminoalkane Derivatized 
Agarose Gels 
In vitro coagulation tests were conducted with the heparin-
ized agarose gels. Since any prolongation of clotting times could 
be the result of free heparin released from the heparinized gels, 
it was important that heparin levels in the test plasmas could be 
accurately determined. Therefore, all heparin immobilization to 
diaminoalkane derivatized agaroses were performed with tritium 
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labeled heparin. 
Furthermore, carbodiimide reactions must be conducted under 
acidic conditions, typically near a pH of 4.75. At this pH, sul-
fate and sulfamate groups can hydrolyze over a 24 hour period, 
resulting in desulfunation with the concommitant loss of anti-
coagulant potency (93). Heparin was therefore immobilized to 
diaminoalkane derivatized surfaces with N-ethyl-5-phenylisoxazo-
lium-3-sulfonate, Woodward's Reagent K (94). This reaction in-
volves the ionized form of the carboxylic group and can be con-
ducted over a wide range of pH's. 
Tritium labeled sodium heparin (New England Nuclear) was 
added to a solution containing cold sodium heparin and was N-
acetylated according to the procedures in Section 2.1.1. This 
3H-N-acetylated heparin had a specific activity of 43,114 ~ 1,048 
dpm/mg. 
Sixty-eight milligrams of Woodward's Reagent K was added to 
a 100 ml solution of pH 7.4 phosphate buffered saline containing 
8.0 mg/ml tritium 1abeled N-acetylated heparin and the carboxylic 
groups on the heparin were activated for 8 hours at 2-40 C. This 
coupling step, similar to the carbodiimide reactions, entails the 
coupling of the Woodward's Reagent K to heparin carboxylic groups 
to form reactive intermediate compounds. Based on conductimetric 
titrations of heparin, to be discussed in detail in subsequent 
sections, heparin contains 1.68 X 10-6 moles of carboxylic func-
tional groups per mg of heparin. The amount of Woodward's Reagent 
K added in all heparin immobilization reactions is a sufficient 
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quantity to activate a maximum of 20% of the total carboxylic 
groups. This activation of a maximum of 20% of the total car-
boxylic groups is of vital importance in retaining heparin activ-
ity and is discussed further in subsequent sections. 
Ten milliliters of the above carboxylic activated, tritium 
labeled N-acetylated heparin solution was added to 4 ml of each 
diaminoalkane derivatized agarose. The mixtures were gently 
stirred for 24 hours at 40 C. The Woodward's Reagent K reaction 
scheme for coupling heparin to primary amines on the diamino-
alkane derivatized agarose is shown in Figure 8. The gels were 
then repeatedly washed with pH 7.4 phosphate buffered saline in 
50 ml increments in a sintered glass funnel, collecting each wash-
ing for heparin quantitation by liquid scintillation counting of 
tritium levels in resultant wash solutions, a tritium background 
of 24.5 cpm was subtracted from all tritium samples. A total of 
twenty, 50 ml washings were used for each gel, typically heparin 
was not observed in wash solutions after the tenth washing. 
The heparinized gels were then suction dried, still hydrated 
however, and 10 ml of 2 M ethanolamine was added to each heparin-
ized gel to react any possible remaining Woodward's Reagent K 
activated carboxylic groups on the immobilized heparin. The gels 
were stored 24 hours at 2-40C in the ethanolamine solutions after 
which they were again repeatedly washed in pH 7.4 buffered saline, 
no heparin was detected in these wash solutions. The gels were 























































































































































2.4.2 Heparin Coupling to 
Diaminoalkane Derivatized 
Sepharose 6-MB 
N-acetylated heparin was coupled to diaminobutane and 
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diaminododecane derivatized Sepharose 6-MB in an analogous fash-
ion to that described in Section 2.4.1. After one month storage 
and subsequent washing, N-acetylated heparin was coupled to the 
diaminoalkane derivatized Sepharose 6-MB beads via amide linkages 
using the condensing agent, Woodward's Reagent K. Sixty-eight 
milligrams of Woodward's Reagent K was added to a 100 ml pH 7.4 
phosphate buffered saline solution containing 8.0 mg of non-
labeled N-acetylated heparin per ml of solution. This is a suf-
ficient quantity of Woodward's Reagent K to activate a maximum of 
20% of the total carboxylic groups present in the 800 mg of N-
acetylated heparin. The carboxylic groups were first activated 
for 8 hours at 2-4oC. The activated heparin solution was then 
added to 3.0 grams of either suction dried diaminobutane or di-
aminododecane derivatized Sepharose 6-MB beads, which were then 
rotated in a closed vessel at approximately one revolution per 
second for 4 hours at 220C followed by 24 hours at 2-4oC. The 
heparinized Sepharose 6-MB beads were then repeatedly washed in 
pH 7.4 phosphate buffered saline and added to 100 ml of 2 M 
ethanolamine in pH 7.4 phosphate buffered saline. The gels were 
then stored 24 hours at 2-4oC in the ethanolamine solution to 
react any possible Woodward's Reagent K activated carboxylic 
groups on the immobilized heparin. The gels were then again re-
peatedly washed with pH 7.4 phosphate buffered saline and stored 
stored at 2-40 C in buffered saline until further evaluation. 
Heparinized gels were not stored longer than 2 weeks under any 
circumstances. The immobilization of N-acetylated heparin to 
Sepharose 6-MB by Woodward's Reagent K is exactly analogous in 
that previously depicted in Figure 8. 




Heparin was coupled to diaminobutane and diaminododecane de-
rivatized cellulose sheets, after one month storage and subsequent 
washing, via an amide linkage, involving heparin cat~boxylic groups 
and the terminal primary amines on the derivatized cellulose using 
Woodward's Reagent K. 
A 100 ml solution of pH 7.4 phosphate buffered saline, con-
taining 8.0 mg/ml of nonlabeled N-acetylated heparin was first 
activated by adding 68.0 mg of Woodward's Reagent K. After adding 
the Woodward's Reagent K to the heparin solution, the carboxylic 
groups are first activated for 8 hours at 2-40 C. 
The above solution was then added to approximately 25 cm2 of 
either diaminobutane or diaminododecane derivatized cellulose 
sheets and allowed to react for 4 hours at 220 C followed by 24 
hours at 2-40 C. The complete reaction scheme for the Woodward's 
Reagent K coupling of heparin to the primary amines of the deri-
vatized cellulose is shown in Figure 8. 
The immobilized heparin cellulose sheets were then washed 
with pH 7.4 phosphate buffered saline and 100 ml of 2 M ethanol-
amine was added to react any possible remaining Woodward's Rea-
gent K activated carboxylic groups on the immobilized heparin. 
The heparinized cellulose sheets were stored at 2-40 C in the 
ethanolamine solution for 24 hours, after which they were re-
peatedly washed with pH 7.4 phosphate buffered saline. The di-
aminobutane and diaminododecane mediated, immobilized heparin 
cellulose sheets were then vacuum dried and stored under vacuum 
dessication until needed for additional testing. 
2.4.4 Heparin Immobilization to 
Sepharose 4-B Beads Via 
Divinylsulfone 
Tritium labeled N-acetylated heparin was coupled to Sepha-
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rose 4-B beads via a divinylsulfone intermediate. Ten grams of 
suction dried Sepharose 4-B (Pharmacia Fine Chemicals, Inc.) was 
added to 10 ml of 0.5 M Na 2C03 with 1.2 ml of divinylsulfone and 
stirred for 2 hours at 220 C. The above divinylsu1fone activated 
Sepharose 4-B beads were then washed with phosphate buffered sa-
line and suction dried with a sintered glass funnel. Four grams 
of the divinylsu1fone activated Sepharose 4-B beads were added to 
10 m1 of 0.5 M Na 2C03 containing 100 mg of tritium labeled N-
acetylated heparin, specific activity 43,114 dpm/mg, and the re-
action contents were rotated at approximately one revolution per 
second for 24 hours. The gels were then repeatedly washed with pH 
7.4 phosphate buffered saline in 50 m1 increments in a sintered 
glass funnel, collecting each washing for heparin quantitation via 
liquid scintillation counting. A total of twenty, 50 ml washing 
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were used; no heparin was detected after the sixth washing. The 
divinylsulfone coupled heparinized Sepharose 4-B gels were stored 
in the pH 7.4 buffered saline until further evaluations. The 
divinylsulfone heparin immobilization reaction is analogous to 
Figure 6. 
2.5 Quantification of Immobilized 
Heparin 
2.5.1 Heparin Immobilized to 
Oiaminoalkane Oerivatized 
Agaroses 
The quantity of heparin immobilized to the diaminoalkane aga-
roses were determined by the difference between the initial amount 
of tritium labeled N-acetylated heparin, specific activity 43,114 
dpm/mg, added to each gel and the summation of the total amount of 
heparin present in the sequential 50 ml rinse solutions, see Sec-
tion 2.4.1. 
2.5.2 Heparin Immobilized to 
Oiaminoalkane Derivatized 
Sepharose 6-MB 
Tritium labeled sodium heparin was added to a solution of 
cold sodium heparin, which was then acetylated according to the 
procedures in Section 2.1.1. This N-acetylated heparin had a 
specific activity of 205,163 ~ 807 dpm/mg. This tritium labeled 
N-acetylated heparin was then coupled to the diaminobutane and 
diaminododecane derivatized Sepharose 6-MB beads using the exact 
procedures described in Section 2.4.2. These tritium heparin 
coupling reactions were conducted in parallel with the cold heparin 
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coupling reactions using the same batches of diaminoalkane deri-
vatized Sepharose 6-MB beads. After repeated washings, following 
the procedures described in Section 2.4.1, known volumes of the 
tritium labeled immobilized heparin gels (~ 2.0 ml) were first 
dissolved with concentrated sulfuric acid to which ethanol was 
added, analogous to the procedures for determined degrees of di-
aminoalkane coupling to Sepharose 6-MB beads and cellulose sheets 
in Sections 2.3.2 and 2.3.3 respectively. Two hundred and fifty 
microliters of the above solutions were then added to 15 m1 of 
scintillation fluid and tritium levels were counted. Each acid 
dissolved tritium labeled heparinized gel was counted in tripli-
cate. A tritium background level of 24.5 cpm was subtracted from 
all tritium samples. 
2.5.3 Heparin Immobilization to 
Diaminoalkane Derivatized 
Cellulose Sheets 
Heparin immobilization to diaminoa1kane derivatized cellulose 
sheets was conducted analogously to that described in Section 
2.5.2. Known surface areas of diaminobutane and diaminododecane 
derivatized cellulose sheets were reacted with tritium labeled N-
acetylated heparin exactly according to the procedures described 
in Section 2.4.1 One hundred milliliters of carboxylic activated 
tritium labeled N-acetylated heparin, specific activity equaling 
205,163 ~ 807 dpm/mg, was added to known surface areas of each 
diaminoalkane derivatized cellulose sheet (~ 25 cm2) which were 
allowed to react as described in Section 2.5.2. These tritium 
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labeled heparin immobilization reactions were conducted in paral-
lel with the cold heparin coupling reaction using the same batch 
of diaminoalkane derivatized cellulose sheets. 
After repeated washings with pH 7.4 phosphate buffered sa-
line, the tritium labeled, immobilized heparin samples were first 
vacuum dried and then dissolved in sulfuric acid followed by 
ethanol, as described in Section 2.3.4. The amount of heparin 
immobilized to the diaminoalkane derivatized gels was then deter-
mined by liquid scintillation counting of the above solutions. 
2.5.4 Heparin Immobilization to 
Sepharose 4-B Beads Via 
Oivinylsulfone 
The quantity of heparin immobilized via divinylsulfone to 
Sepharose 4-B was determined by the difference between the amount 
of tritium labeled N-acetylated heparin, specific activity 43,114 
dpm/mg, initially added and the summation of the total amounts of 
heparin present in the sequential 50 ml rinse solutions, see 
Section 2.4.4. 
2.6 Conductimetric Titrations of 
Sulfate, Sulfamate and Carboxylic 
Groups on Functional Group 
Derivatized Heparins 
Conductimetric titrations of heparin (95) provide a conveni-
ent quantitation of sulfate and carboxylic groups. Sodium heparin 
is first converted into the acid form by elution of a known 
quantity of heparin, dissolved in neutral deionized distilled 
water, through a column of previously washed AG 50W-X2 cationic 
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exchange resin (BioRad Laboratories). The effluent is collected 
until only neutral water exists in the column and is then diluted 
to a final volume of 150 m1. 
The solution is titrated with standardized NaOH while mea-
suring solution conductivity with a protable conductivity meter 
(Markson Science, Inc.) vs volume NaOH solution added. The con-
ductance of the sample solution, initially high due mainly to the 
contribution of mobile protons on the -S03H groups (specific 
conductance A+ = 350), decreased linearly as -S03H protons are 
neutralized by hydroxide ions and are replaced by Na+ ions (A+ = 
50). After all of the -S03H protons are neutralized, the curve 
levels off. This plateau region corresponds to carboxylic group 
proton dissociation. Conductance barely changes in this region 
due to the compensatory effects from carboxylic proton neutraliza-
tion and increased Na+ ion concentrations. After dissociation and 
neutralization of all carboxylic protons, conductance sharply in-
creased primarily due to OH ion contributions (A = 198). Extra-
po1ation of the three branches of the conductimetric curves gives 
two intersection points, the first corresponding to the number of 
-S03H groups while the second corresponds to the number of -GOOH 
groups. Changes in the number of titratable carboxylic groups on 
derivatized heparins, relative to the N-acetylated heparin start-
ing material, provides a convenient measure of the degree of 
carboxylic derivatization. 
2.7 Proton Nuclear Magnetic Resonance 




Forty milligrams per ml solutions of sodium heparin and func-
tional group derivatized sodium heparins in deuterium oxide 
(Stohler Isotopes) with a 2,2,-dimethyl-2-silapentane-5-sulfonate 
(DDS) reference compound were evaluated. Proton nmr spectra were 
obtained with a Varian SC 300 nmr spectrometer at ambient room 
temperature at the University of Utah nmr center. 
2.8 Transmission Mode Infrared 
Spectroscopy of Cellulose 
Sheets 
Transmission mode IR spectra of underivatized cellulose 
sheets, diaminoalkane derivatized cellulose sheets and heparin im-
mobilized diaminoalkane cellulose sheets were obtained with a 
Beckman 620 MX IR spectrometer. Transmission IR spectra were also 
obtained for sodium heparin and functional group derivatized sodi-
urn heparin with KBr pellets. 
2.9 X-Ray Photoelectron Spectroscopy 
Surface Evaluations 
X-ray photoelectron spectroscopy (XPS) was conducted on cel-
lulose, diaminoalkane derivatized cellulose, heparin immobi'lized 
diaminoalkane derivatized cellulose, and on the immobilized hepa-
r;n surfaces after contact with protein solutions and plasma. 
XPS spectra were also obtained on N-acetylated heparin powder. 
All XPS polymer spectra were obtained only for flat surfaces 
(bead geometries were not evaluated) with a Hewlett-Packard model 
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5950B XPS spectrometer at the University of Utah Surface Analysis 
Laboratory. 
2.10 In Vitro Coagulation Assays 
2.10.1 Functional Group 
Derivatized Heparin 
The anticoagulant activities of the N-acetylated heparin, 
the hydroxyl group derivatized heparins and the carboxylic group 
derivatized heparins were determined by activated partial thrombo-
plastin time (APTT) assay methods (96). Bovine blood was col-
lected in 3.8% sodium citrate, 9 parts blood to 1 part citrate, 
and centrifuged at 5000 g for 15 minutes. The supernatant plasma 
was collected and pooled for subsequent APTT testing. Plasma was 
stored at 2-40C for no longer than six hours, at which time it 
was discarded. 
Activated partial thromboplastin time tests were conducted by 
first incubating 100 ~l of plasma, either plasma containing known 
unit activities of heparin for preparation of calibration curves 
or plasma containing known weight concentrations of derivatized 
heparin for determining derivatized hepar'in activity, with 100 ~l 
of activated thromboplastin reagent (Ortho Pharmaceutics) at 370C 
for five minutes. One hundred microliters of 0.3 M CaC1 2 in dis-
tilled water is then rapidly added to the incubated plasma and 
clotting times (APTT) were determined with a Fibrometer (Beckman). 
An APTT (seconds) vs heparin activity in the plasma (units/ml) is 
first prepared with plasma heparinized in 0.1 unit/ml increments. 
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A linear relationship is typically observed between 0.0 and 0.5 
units/ml of heparin; if r, linear regression correlation coeffi-
cient, is less than 0.90 the plasma was discarded without further 
testing. After preparation of the APTT vs plasma heparin activity 
curve, known weight concentrations of the functional group deri-
vatized heparins were prepared with the same plasma used to ob-
tain the APTT calibration curve and APTT was determined as with 
the standard heparin activity calibration plasmas. Unheparinized 
plasma and selected standard heparin calibration plasmas were 
periodically evaluated to ensure that coagulation factors had not 
degraded during the course of testing. If control or standard 
heparin activity plasmas deviated from original values, the test-
ing was discontinued and that plasma was discarded. Each plasma 
sample was tested for APTT in triplicate for each batch of plasma 
and derivatized heparin activities were determined based on a 
minimum of 6 batches of plasma collected from different animals at 
different times. 
Having previously prepared the APTT plasma heparin activity 
curve and determined APTT for known heparin plasma concentrations 
(mg/ml), the plasma heparin activity (units/ml) is determined 
from the calibration curve and the derivatized heparin activity is 
then determined (units/mg) 
2.10.2 Immobilized Heparin Gels 
Activated partial thromboplastin times were also conducted on 
plasmas exposed to immobilized heparin gels to determine spacer 
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arm length effects on immobilized heparin anticoagulant activity 
and possible differences in anticoagulant activity associated with 
immobilization via different heparin functional groups. The APTT 
vs plasma heparin activity curve was prepared as described above 
in Section 2.10.1. Various quantities of the heparinized gels 
were then added to 10 ml of the same plasma used to prepare the 
calibration curve. The gels and plasmas were then gently rotated 
at approximately 1 rps for 10 minutes at room temperature and 
then centrifuged at 2500 g for 5 minutes, APTT was then deter-
mined for the supernatant plasmas. Activated partial thrombo-
plastin times were also determined for the diaminoalkane deriva-
tized gels without immobilized heparin, in the same gel volume to 
plasma volume ratio. Free heparin levels in gel exposed plasma 
samples were determined by liquid scintillation counting of the 
tritium labeled heparin, specific activity 43,114 dpm/mg. 




2.11.1 Protein Adsorption from 
Single Component Protein 
Solutions 
Ten milligrams per ml solutions of fraction V bovine albumin, 
essentially fatty acid free (Sigma Chemical Company), purified 
human antithrombin III (American Red Cross) and purified bovine 
fibrinogen (IMCO) in pH 7.4 phosphate buffered saline were pre-
pared. The pHis of the albumin, ATIII and fibrinogen solutions 
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were 7.2, 7.3 and 7.3 representively. Portions of the dessicated 
heparinized diaminoalkane derivatized cellulose sheets (~ 2-5 cm2) 
were first hydrated for 30 minutes in pH 7.4 phosphate buffered 
saline, dried with lens cleaning paper and then placed in the 
above solutions for 2 hours at room temperature. The heparinized 
cellulose samples were then removed from the protein solutions and 
placed in 20 ml of PBS and rotated at 1 rps for 10 minutes. The 
samples were then removed and placed in 20 ml of fresh PBS and 
rotated an additional 10 minutes at which time the samples were 
vaccum dried and stored under vacuum dessication for XPS surface 
analysis. 
2.11.2 Protein Adsorption from 
Bovine Plasma 
Portions of the heparinized diaminoalkane derivatized cellu-
lose sheets (~ 2-5 cm2) were hydrated in pH 7.4 phosphate buffer 
saline for 30 minutes, dried with lens cleaning paper and then 
placed in bovine plasma, prepared from calf's blood freshly col-
lected in Na citrate, for 2 hours at room temperature. The hepa-
rinized diaminoalkane derivatized cellulose samples were then 
rinsed as described in Section 2.11.1 above, vacuum dried and 
stored under vacuum dessication for subsequent XPS analysis. 
2.12 Platelet Retention and Platelet 




Platelet retention and a-granule release were determined by 
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passing whole blood through columns containing respective gels and 
determining platelet levels and plasma PF4 levels in fractions 
collected existing the columns. Polypropylene columns were packed 
with 1 cc of each respective diaminoalkane gel (without heparin) 
and each diaminoa1kane spacer arm mediated heparin immobilized 
gel. Control materials consisted of untreated Sepharose 6-MB gel. 
Twenty-five milliliters of calf's blood, freshly collected via a 
double syringe technique in citrate, was perfused through each 
column at a controlled flow rate of 2.0 cc/min with a peristaltic 
pump, and 5.0 cc whole blood fractions were sequentially collected 
exiting each column. One milliliter of whole blood was removed 
from each fraction for hematocrit and platelet level determination 
using a Coulter Counte~R). The remaining portion of each blood 
fraction was immediately cooled in an ice water bath for between 
30 minutes and 2 hours. After 25 cc of whole blood perfusion, 15 
cc of PBS was perfused through each column to rinse the gels, fol-
lowed by 15 cc of 1.0 M NaCl to elute PF4 bound to immobilized 
heparin (97). These fractions were collected and placed in the 
ice water bath as previously described. Platelet poor plasma was 
then obtained from the cooled blood fractions by centrifugation. 
These plasma samples were immediately frozen (-20oC) for later 
PF4 analysis. The PBS and 1.0 M NaC1 fractions were similarly 
centrifuged and the resultant supernatants were collected and fro-
zen for PF4 analysis. Each material was ran in triplicate using 
different calves. 
Platelet factor 4 levels in collected plasma and buffer frac-
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tions were determined by bovine PF4 radioimmunoassay techniques 
using bovine PF4 RIA reagents (Abbott Laboratories). The test is 
a competitive radioimmunoassay in which nonradioactive PF4 in 
plasma, and buffer, competes with a constant amount of l25 I_PF4 
for binding sites on a constant limited amount of bovine PF4 anti-
serum. The percentage of radioactive PF4 bound to the antiserum 
is therefore inversely proportional to the concentration of non-
labeled PF4 in the test samples. To 250 ~l of the l25 I_PF4 solu-
tion is added either 50 ~l of dilution buffer, nonlabeled bovine 
PF4 standards in concentrations ranging from 50 ng/ml to 1000 
ng/ml, or 50 ~l of the test sample. Two hundred and fifty micro-
liters of PF4 antiserum is added and the tubes are incubated at 
room temperature for 2 hours after which 1 ml of 73% saturated 
ammonium sulfate is added. The tubes are then incubated between 
10 and 60 minutes and then centrifuged at 1500 g for 20 minutes. 
The supernatant is carefully decanted into liquid waste and the 
excess supernatant on the rim of each tube is blotted with tissue 
paper. The total Iodine-125 in the precipitate is then counted 
with a gamma counter. The percent bound, expressed as cpm of 
standard or test sample divided by the total cpm in 250 ~l of the 
l25 I_PF4 solution multiplied by 100, is determined for each tube. 
A standard curve is then prepared by plotting percent bound vs 
standard PF4 concentration. By locating percent bound of the un-
known test sample on the standard curve, the concentration of PF4 
in the test sample is determined. Each PF4 standard and unknown 
test sample, plasma or buffer solution, is evaluated in triplicate. 
CHAPTER 3 
RESULTS 
3.1 Diaminoalkane Coupling to 
Polymer Substrates 
3.1.1 Diaminoa1kane - Agaroses 
The degrees of diaminoa1kane coupling to respective agarose 
gels was determined by the manufacturer and are presented in 
Table IV. 
3.1.2 Diaminoa1kane Coupling to 
Sepharose 6-MB 
The degrees of diaminoalkane coupling to Sepharose 6-MB 
beads, to be used in platelet retention and PF4 release experi-
ments, were determined by a carbodiimide reaction with an excess 
of carbodiimide and 14C-acetic acid. After thorough washing in 
pH 7.4 phosphate buffered saline, known volumes of 14C-acetate 
coupled diaminobutane and diaminododecane derivatized Sepharose 6-
MB gels were digested in concentrated acid, diluted with ethanol 
and counted for carbon-14. Quenching was determined for each sam-
ple by H-number methods on a Beckman LS-7500 liquid scintillation 
counter. Based on blank scintillation fluid vials, a carbon-14 
background of 15.0 cpm was subtracted from the total counts of 
each sample and corrected d?m, calculated based on origin counting 
efficiencies, were used in subsequent calculations. The moles of 
Table IV 


















14 C-acetate coupled per cubic centimeter of gel plus or minus one 
standard deviation, based on three assays, is presented in Table 
V below. These values were taken as the amount of accessible 
free primary amines, coupled diaminoalkanes with a free primary 
amine, capable of covalent coupling with heparin. 
3.1.3 Diaminoalkane Coupling to 
Cyanogen Bromide Activated 
Cellulose Sheets 
The degrees of diaminoalkane coupling to the cyanogen bro-
mide activated cellulose sheets were determined by a carbodiimide 
reaction with an excess of carbodiimide and l4C-acetate acid. 
After thorough washing with pH 7.4 phosphate buffered saline, 
known surface areas of the l4C-acetate coupled diaminobutane and 
diaminododecane derivatized cellulose sheets were digested in con-
centrated acid, diluted with ethanol and counted for carbon-14. 
Quenching was determined for each sample by H-number methods and a 
carbon-14 background of 15.0 cpm was substracted from each sample. 
Total dpms were then recalculated based on the corrected cpm 
values and these background corrected dpm values were used in sub-
sequent calculations. 
The moles of 14C-acetate coupled per square centimeter of 
cellulose plus or minus one standard deviation, based on three 
assays, are presented in Table VI below. These values were taken 
as the amount of accessible free primary amines, coupled diamino-
alkanes with a free primary amine, capable of covalent coupling 
with heparin. 
Table V 






Degree of Coupling 
(11 moles) 
cc gel 
2.29 + 0.31 
2.05 + 0.12 
Diam;noalkane Coupling to 





Degree of Coupling 
( 11 moles) cm2 
0.048 + 0.003 
0.052 + 0.005 
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3.2 Heparin Coupling to Polymer 
Substrates 
3.2.1 Heparin Coupling to 
Diaminoalkane-Agaroses 
The amount of heparin coupled to the respective diaminoal-
kane-agarose gels was determined by the difference between the 
total amount of heparin used in the immobilization reactions, 
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specific activity 43,114 dpm/mg, and the total amount of heparin 
collected in subsequent gel washings. For convenience sake, the 
washings were pooled and tritium levels were determined on the 
pooled washings having a total final volume of 500 ml for each 
gel, no heparin was detected in fraction's after the tenth frac-
tion. Quenching was determined for each sample by H-number meth-
ods using a Beckman LS-9000 liquid scintillation counter and 
tritium background levels were substracted from each sample. The 
amount of tritium labeled heparin, specific activity 43,114 dpm/ 
mg, coupled to each diaminoalkane gel is presented in Table VIr 
below. These heparin immobilized gels were then used in subse-
quent clotting time tests. 
3.2.2 Heparin Coupling to 
Diaminoalkane Derivatized 
Sepharose 6-MB 
The degrees of heparin coupling to diaminobutane and diamino-
dodecane derivatized Sepharose 6-MB beads was determined for an 
exact parallel reaction with tritium labeled heparin, specific 
activity 205,163 ~ 807 dpm/mg. After thorough washing, known 
volumes of gels were digested in concentrated acid, diluted with 
Table VII 








Degree of Heparin 
Immobilization 
( mg ) 








ethanol and counted for tritium levels. Quenching was deter-
mined for each smaple by H-number methods using a Beckman LS-7S00 
liquid scintillation counter. Based on control scintillation 
fluid samples a tritium background level of 24.S cpm was sub-
tracted from each sample and the corrected dpm was determined 
based on the original counting efficiency, assays were conducted 
in triplicate. The values obtained for heparin coupling with the 
tritium labeled heparin plus or minus one standard deviation, 
were assumed to be equal to the degree of coupling for the non-
labeled heparin coupling reactions and are presented in Table 
VIII below. 
3.2.3 Heparin Coupling to 
Diaminoalkane Derivatized 
Cellulose 
The degrees of heparin coupling to diaminobutane and diamino-
dodecane derivatized cellulose sheets was determined for an exact 
parallel reaction using tritium labeled heparin, specific activ-
ity 20S,163 ~ 807 dpm/mg. After thorough washing, known surface 
areas of the immobilized heparin materials were digested in con-
centrated acid, diluted with ethanol and counted for tritium 
levels. Quenching was determined for each sample and background 
tritium levels were subtracted for each sample as described in 
Section 3.2.2. The values obtained for heparin coupling with 
tritium labeled heparin plus or minus one standard deviation were 
assumed to equal the degrees of coupling for the nonlabeled hepa-
r;n coupling reactions and are presented in Table IX. 
Table VIII 







Degree of Heparin 
Immobilization 
( rna 
cc swolien gel) 
1.46 + 0.07 
1 .48 + 0.09 





Degree of Heparin 
Immobilization 
(~) 
6.06 + 0.98 
5.18 + 0.57 
80 
3.2.4 Heparin Coupling to 
Sepharose 4-B Via 
Divinylsulfone 
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As in Section 3.2.1, the degree of heparin coupling via di-
vinylsulfone to Sepharose 4-B beads was determined by the differ-
ence between the total amount of heparin, specific activity 
43,114 dpm/mg, used in the immobilization reaction and the total 
amount of heparin collected in subsequent washings. For conveni-
ence sake, the washings were pooled for the first 10 wash frac-
tions and tritium levels were determined for the pooled washings, 
a total final volume of 500 ml. The amount of tritium labeled 
heparin immobilized via a divinylsulfone bridge was determined to 
be 2.05 mg/cc gel. 
3.3 Conductimetric Titrations of 
Functional Group Derivatized 
Heparins 
3.3.1 Conductimetric Titrations 
of N-acety1ated Heparin 
Conductimetric titration of N-acety1ated heparin were con-
ducted in triplicate. The total amounts of carboxylic and sulfate 
(both sulfate and su1famate) groups per mg of N-acety1ated hepa-
rin, plus or minus one standard deviation, were determined to be 
1.68 X 10-6 ~ 0.08 X 10-6 mole -COO-/mg and 3.05 X 10-6 + 0.18 X 
10-6 mole -SO;/mg respectively. A representative conductimetric 























































































3.3.2 Conductimetric Titrations 
of Carboxylic Derivatized 
Heparin 
The effects of the degree of carboxylic blocking with n-
butylamine on N-acety1ated heparin were determined by sampling 
portions of the carbodiimide reaction with time, sampling times 
were at 1 hour and 20 minutes, 4 hours and 6 hours. Carboxylic 
groups on N-acety1ated heparin were also blocked with 2-amino-
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ethyl hydrogensu1fate via the carbodiimide reaction. Total car-
boxylic groups and sulfate groups, both sulfate and sulfamate, 
were determined based on conductimetric titrations with standard-
ized NaOH solutions for the carboxylic blocked N-acety1ated hepa-
rin and are presented in Table X. Conductimetric titration 
curves for the 1 hour and 20 minutes and the 6 hour n-buty1amine 
samples are presented in Figures 10 and 11. 
The conductimetric titration data provides a convenient means 
for approximately the degree of carboxylic group blocking. Based 
on an initial carboxylic group abundance of 1 .68 ~ moles/mg, the 
percent blockage of the carboxylic groups are 17.9%, 36.9% and 
100% for the n-butylamine reaction at 1 hour plus 20 minutes, 4 
hours and 6 hours reaction time respectively. Similarily the de-
gree of carboxylic blocking for the 2-aminoethy1 hydrogensulfate 
reaction is 10.1%. The relative abundance of sulfate groups pro-
gressively decreases with time, either the result of increased 
molecular weight associated with derivatization or the results of 
acid catalyzed hydrolysis of sUlfate and sulfamate groups. Un-







Carboxylic and Sulfate Groups 
Determinations for Carboxylic 




(1 hr 20 min 1 .38 
reacti on t"ime) 
(4 hr reaction 1 .06 
time) 
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creased derivatization and resultant increased molecular weight; 
however, the loss of sulfates from hydrolysis at pH 4.75 cannot 
be ruled out based on this data. 
3.3.3 Conductimetric Titrations 




Hydroxyl groups on N-acetylated heparin were blocked with n-
butylamine, 2-aminoethyl hydrogensulfate and glycine using the 
crosslinking agent epichlorohydrin. Total carboxylic and sulfate 
groups on hydroxyl derivatized N-acetylated heparin were deter-
mined by conductimetric titrations and are listed in Table XI. 
It is difficult to determine the degrees of hydroxyl group 
derivatization based on the data presented here. As before, one 
expects the relative abundance of carboxylic and sulfate groups 
to decrease with increased derivatization, with the n-butylamine 
and this is found to be the case. This task is further compli-
cated by the high polydispersity, both molecular weight and chemi-
cal structure, of heparin along with the fact that epichlorohy-
drin is a crosslinking agent. Although primary amines on the 
heparin have been blocked, crosslinking between hydroxyl gro~ps on 
heparin molecules cannot be ruled out. 
3.3.3.2 Oivinylsulfone 
Reactions 
Hydroxyl groups on N-acetylated hpearin were blocked with n-
Table XI 
Carboxylic and Sulfate Group Determinations 










n-butylamine 1 .29 2.20 
2-aminoethyl hydrogensulfate 1 .33 2.86 
glycine 1 .71 3.05 
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butylamine, 2-aminoethyl hydrogensulfate and glycine using di-
vinylsulfone as the crosslinking agent. Total carboxylic and sul-
fate on the hydroxyl derivatized n-acetylated heparins were deter-
mined by conductimetric titrations and are listed in Table XII. 
The problems associated with interpreting the conductimetric 
titration data, in regards to determining the degree of derivati-
zation, discussed for the epichlorohydrin reactions applies 
equally, if not more so, with the divinylsulfone reactions. Cer-
tainly crosslinking is expected between hydroxyl groups on heparin 
molecules with divinylsulfone. 
3.4 Proton Nuclear Magnetic 
Resonance Spectroscopy of 
Heparin 
The proton nmr spectra for untreated sodium heparin, liter-
ally !lout of the bottle," and N-acetylated sodium heparin are 
shown in Figures 12 and 13 respectively. Broad carbon proton 
peaks are observed between ~ 2.6 and ~ 4.8 ppm with a large sol-
vent peak at 3.96 ppm. A triplet peak is observed at 0.98 ppm and 
an apparent quartet is also observed at 3.04 ppm for the untreated 
heparin. After acetylation and dialysis, the broad carbon proton 
peaks and the solvent peak appear unchanged; however, the triplet 
at 0.98 ppm and the quadruplet at 3.04 ppm are no longer present. 
These two peaks must represent impurities in the original heparin 
source that are removed by dialysis. These impurity peaks might 
arise from ethanol used to precipitate the sodium heparin during 
the commercial preparation of the anticoagulant. 
Table XII 
Carboxylic and Sulfate Group Determinations 










n-butylamine 1 .48 2.70 
2-aminoethyl hydrogensulfate 1 .30 3.01 


















3.5 Infrared Spectroscopy 
3.5.1 Functional Group 
Derivat;zed Heparin 
93 
The IR spectrum, transmission mode, for N-acety1ated heparin 
is shown in Figure 14. A broad peak between ~ 3700 and ~ 3000 
cm- 1 arises from hydroxyl and amine proton stretching and the 
characteristic carboxyl anion peak is observed at ~ 1650 cm- l . 
The IR spectrum for the epichlorohydrin reaction with n-butylamine 
is shown in Figure 15. The peak at 2960 cm-1, alkane C-H stretch-
ing, is substantially larger for the n-buty1amine hydroxyl deri-
vatized N-acetylated heparin, relative to the N-acetylated heparin 
starting material. Other than this single peak, the IR spectrums 
for the functional group derivatized heparins are not signifi-
cantly different from the N-acetylated heparin starting material. 
3.5.2 Cellulose Sheet 
Derivatizations 
The IR spectrum, transmission mode, for the soxhlet extracted 
cellulose sheets is presented in Figure 16. Characteristic groups 
include the broad hydroxyl stretching peak between ~ 3700 and 3000 
-1 -1 cm and the carbon-hydrogen stretching peak at ~ 2900 cm . 
After cyanogen activation and diaminoalkane coupling, the carbon-
hydrogen stretching peak increases and a new peak at approximately 
1730 cm- l appears due to the formation of the imidocarbonate 
group from the cyanogen bromide. The IR spectrum for diaminodo-
decane coupling to the cellulose sheet is presented in Figure 17 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































boxyl anion and newly formed amide peaks, both at ~ 1650 cm- l , 
from the heparin are observed. The IR spectrum for heparin 
coupled to diaminododecane derivatized cellulose sheets is pre-
sented in Figure 18 as a representative spectrum. 
3.6 X-Ray Photoelectron 
Spectroscopy 
98 
X-ray photoelectron spectroscopy was conducted on extracted 
cellulose, diaminobutane and diaminododecane derivatized cellu-
lose, heparin powder and heparin immobilized to the respective 
diaminoalkane derivatized celluloses. Flood gun conditions were 
optimized for the initial cellulose material, 0.6 rna and 6.0 eV, 
and those settings were used in all subsequent analyses. Atomic 
percents for various elements were determined by the equation: 
Atomic Percenti = X 100 
where 0i is the photoionization cross section for specific elec-
trons of element i and Ni is the number of scans of the specific 
electrons for the element i. 
3.6.1 XPS Analyses for Cellulose 
Substrates 
The atomic percents of carbon, oxygen and nitrogen were de-
termined and are listed below, including the appropirate photo-
ionization cross sections, in Table XIII. The nitrogen 1Sl/2 
peak is extremely small and probably represents some form of sur-
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Atomic Percent for 
Cellulose Sheets 
Cross Section- Number of 
Electron Type Scans 
1 .00 (1 S 1/2) 10 
1.80 (151/ 2) 20 








out by the high resolution spectrum of the carbon lSl/2 electrons 
shown in Figure 19. Based on the carbon structure of cellulose, 
one would expect two types of carbons to be present, carbon 
atoms bound to a single oxygen and carbon atoms bound to 2 oxy-
gens (glycosidic carbons), in 5:1 proportions respectively. How-
ever, three carbon peaks are observed: peak #1 at 289.44 eV, 
peak #2 at 285.60 eV and peak #3 at 284.00 eV. All peaks are 
corrected to the alkane carbon lSl/2 peak which should occur at 
284.00 eV, approximately 6 eV must be added to each peak. The 
relative peak areas for the three peaks are 12.04%, 66.48% and 
21 .48% respectively. Peaks #1 and #2 therefore, represent the 
cellulose carbon atoms and peak #3, low binding energy, must re-
present surface contamination. The oxygen lSl/2 peak appears as 
a single component peak. 
3.6.2 Diaminoalkane XPS 
Derivatized Cellulose 
Analyses 
The atomic percents of carbon, oxygen and nitrogen are pre-
sented in Table XIV for the diaminoalkane derivatized cellulose 
sheets. 
The atomic percents of nitrogen have increased for both di-
aminoalkane coupled cellulose sheets. These nitrogen atoms arise 
from the imidocarbonate group from the cyanogen bromide activation 
step and the amine groups from the diaminoalkanes. The fact that 
the atomic percent nitrogen is higher for diaminobutane than for 


















































































Atomic Percents for Diaminoa1kane 
Derivatized Cellulose Sheets 
Cross Section- Number of 
Diaminoa1kane Element Electron Type Scans 
Diaminobutane C 1.00- lS l/2 10 
Diaminobutane N 1.80-1S1/ 2 20 
Diaminobutane 0 2.93-1S1/ 2 10 
Diaminododecane C 1.00-1S1/ 2 10 
Diaminododecane N 1.80-151/ 2 20 











carbon associated with the diaminododecane spacer arm; however, 
the atomic percent of carbon for the diaminododecane derivatized 
cellulose was actually lower than for the diaminobutane deriva-
tized cellulose. High resolution carbon lSl/2 spectra for the 
diaminobutane and diaminododecane derivatized cel1u1oses are pre-
sented in Figures 20 and 21, respectively. Three major carbon 
lS l / 2 peaks are observed with both spectrums; however, the low 
energy, alkane carbon portions of the total carbon spectra pro-
gressively increases with the diaminobutane and diaminododecane 
derivatized ce1luloses as would be expected. With the diamino-
butane cellulose, the alkane carbon represents 33.7% percent of 
the total carbon while the alkane carbon peak for the diaminodo-
decane derivatized cellulose represents 39.2% of the total car-
bon. It must be remembered, however, that a larger portion of 
that carbon peak is due to surface contamination as discussed in 
Section 3.6.1. 
3.6.3 Sodium Heparin XPS 
Analyses 
The main elements found in N-acetylated sodium heparin were 
sodium, sulfur, carbon, nitrogen and oxygen. The atomic percents 
of sulfur, carbon, nitrogen and oxygen, neglecting sodium which 
was not analyzed in all other spectra, are presented in Table XV. 
The high resolution carbon lSl/2 spectrum is very similar to the 
cellulose spectrum and is not shown. The sulfur 2S l /2 peak 




















































































































































































































































Atomic Percents for 
N-acetylated Heparin 
Cross 5ection- Number of 
Electron Type 5cans 
1 .43-251/ 2 10 
1.00-151/ 2 10 
2.93-151/ 2 10 








3.6.4 Heparin Immobilized to 
Diaminoalkane Derivatized 
Cellulose 
The atomic percents of sulfur, carbon, oxygen and nitrogen 
for heparin immobilized to diaminoa1kane derivatized celluloses 
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are presented in Table XVI. 
The high resolution carbon 15 spectra for heparin immobi-
lized to diaminoalkane celluloses are similar to the respective 
spectra obtained for the diaminoalkane celluloses, both showing 
large alkane carbon low binding energy peaks. The high resolu-
tion sulfur 251/ 2 spectra for heparin immobilized to diaminobu-
tane and diaminododecane celluloses are presented in Figures 22 
and 23 respectively, peak maxima occurring at 231.88 and 231.57 
eV respectively. The atomic percents of sulfur for the two sur-
faces are very low, 0.3% for both diaminobutane and diaminodode-
cane spacer arms; however, it should be noted that pure heparin 
had only 5.3 atomic percent sulfur. 
3.7 Activated Partial 
Thromboplastin Time 
Test 
3.7.1 Functional Group 
Derivatized Heparins 
The activities of the N-acetylated heparin and the carboxylic 
derivatized heparins determined by APTT tests, plus or minus 95% 
confidence limits, are presented in Table XVII. The activities of 
the hydroxyl derivatized heparins, plus or minus 95% confidence 
limits, are presented in Table XVIII. 
Table XVI 
Heparin Immobilized to Diaminoa1kane 
Derivatized Ce11u1oses 
Cross Section- Number of 
Spacer Arm Element Electron Type Scans 
Diaminobutane S 1.43-2S1/ 2 50 
Oiaminobutane C 1.00-1S1/ 2 10 
Diaminobutane 0 2.93-1S 1/ 2 10 
Diaminobutane N 1.80-1S1/ 2 20 
Diaminododecane S 1 . 43-2S1 /2 50 
Diaminododecane C 1.00-lS1/ 2 10 
Oiaminododecane 0 2.93-1S 1/ 2 10 













































































































































































































































































































































































































































Anticoagulant Activity of Carboxylic 
Group Derivatized Heparins 
R Activity 
(Alkyl Group) cf Derivatization (units/mg) io 
Control 0 157 + 14 
(N-acetylated) 
n-butylamine 17.9 132 + 8 
n-buty1amine 36.9 128 + 8 
n-buty1amine 100.0 0 













Activities of Hydroxyl Group 
Derivatized Heparin 
R 













124 + 11 
132 + 5 
121 + 8 
113 + 5 
133 + 10 
130 + 14 
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3.7.2 Immobilized Heparin Gels 
The APTT results for plasma obtained for 0.5 ml of heparin 
immobilized to diaminoalkane derivatized agarose gels incubated 
10 minutes at room temperature with 10 ml of plasma is presented 
in Figure 24, the region delineated by the dashed lines repre-
sents the baseline APTT of control plasma, plus or minus one 
standard deviation. The open circles represent mean APTT values 
for heparin immobilized via different diaminoalkane spacer arm 
lengths, indicated by the number of carbon atoms in the respec-
tive diaminoalkane spacer arm. The solid circles represent APTT 
values obtained for the respective diaminoalkane-agarose without 
immobilized heparin, one standard deviation is represented by the 
bar markers on each point. Activated partial thromboplastin 
times for plasma obtained from 1 ml of heparin immobilized gels 
incubated with 10 ml of plasma follow a similar pattern; APTT for 
heparin immobilized via 2 and 4 carbon unit diaminoalkane spacer 
arms ranged between 63.5 and 81.8 seconds; however, mean APTT for 
the 8 and 10 carbon unit diaminoalkane spacer arms were 106.2 and 
295.2 seconds respectively while heparin immobilized via the 12 
carbon unit spacer arm produced APTT times greater than 30 min-
utes, no clotting was ever observed. When 0.5 ml of the heparin 
immobilized via d;vinylsulfone to Sepharose 4-8 beads was incu-
bated 10 minutes with plasma, the resultant supernatant plasma had 
an APTT of 54.1 + 7.8 seconds, comparable to heparin immobilized 
to comparable length diaminoalkane gels. 
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Figure 24. Activated partial thromboplastin time 
versus dimainoalkane carbon number. 
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scintillation counting. The dpm/ml, after background subtrac-
tion, and the calculated concentrations of free heparin for the 
above plasmas are presented in Table XIX. 
Although free heparin plasma concentrations were found to 
increase with increased spacer arm length, the plasma dpm/ml val-
ues are only slightly over background levels. Furthermore, to 
produce APTT clotting times greater than 200 seconds would re-
quire a minimum of .45 units/ml of heparin. This concentration of 
hepari.n would produce 123 dpm/ml in the test plasma. Even in 
plasmas with APTT greater than 30 minutes, only 28.97 dpm/ml was 
measured. It can therefore be concluded that the increased clot-
ting times associated with the immobilized heparin gels are not 
due to the release of heparin from the gels. 
3.8 XPS Analyses of Heparinized 
Surfaces After Protein 
Adsorption 
3.8.1 Single Component Proteins 
Solutions 
Heparin immobilized diaminobutane and diaminododecane cel1u-
lose surfaces were exposed for 2 hours to 10 mg/ml solutions of 
ATIII, albumin and fibrinogen. After rinsing, the atomic percents 
for sulfur, carbon, nitrogen and oxygen were determined. Respec-
tive elemental atomic percents for heparin immobilized to diamino-
butane and diaminododecane derivatized ce11u10ses are presented in 
Tables XX and XXI. 
The high resolution spectra of the sulfur 2S 1/ 2 electrons for 
Table XIX 
Free Heparin Concentrations in 
APTT Test Plasmas 
Plasma Heparin 
Mean APTT Concentration 
Spacer Arm (Sec) (dpm/ml) 
Oiaminoethane 57.0 7.47 
Diaminobutane 53.4 12. 18 
Oiaminooctane 51 .4 11 .42 
Oiaminodecane 124.1 8.41 
Oiaminodecane 295.2 15.05 
Diaminododecane 174.9 22.52 
Oiaminododecane >1500 28.97 












*Based on a specific activity of 43,114 dpm/mg and an 








Atomic Percents for Heparinized 
Diaminobutane Cellulose Surface 
Cross Section- Number of 
Element Electron Type Scans 
S 1.43-2S1/ 2 50 
C 1.00-lS1/ 2 10 
N 1.80-1S1/ 2 10 
0 2.93-151/ 2 10 
S 1.43-2S1/ 2 50 
C 1.00-1S1/ 2 10 
N 1.80-1S1/ 2 10 
0 2.93-151/ 2 10 
S 1.43-251/ 2 50 
C 1.00-1S1/ 2 10 
N 1.80-151/ 2 20 






















Atomic Percents for Heparinized 
Diaminododecane Cellulose Surfaces 
Cross Section- Number of 
Element Electron Type Scans 
S 1 · 43-2S 1/2 50 
C 1.00- lS l/2 10 
N 1 .80-1 S, /2 10 
0 2.93-1S1/ 2 10 
S 1.43-2S1/ 2 50 
C 1.00-1S1/ 2 10 
N 1.80-1S1/ 2 10 
0 2.93-1S1/ 2 10 
S 1 .43-2S1 /2 50 
C 1.00-1S1/ 2 10 
N 1.80-1S1/ 2 20 
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heparin immobilized to diamincbutane surfaces exposed to 10 mg/ml 
solutions of ATIII, albumin and fibrinogen are shown in Figures 
25, 26 and 27 respectively. It is readily seen that no sulfur 
2S1/2 peaks occur near 232 eV as was the case for the heparin 
powder sulfur 2S1/2 electrons and for the immobilized heparin 
surfaces prior to protein adsorption (Figures 22 and 23). Small 
peaks do occur at ~ 226.5 eV for the protein adsorbed heparinized 
diaminobutane surface. The sulfur in heparin is as either a sul-
fate or sulfamate group, therefore heparin sulfur appears at a 
higher binding energy due to the high electronegative environment 
of the sulfur atoms in the sulfate and sulfamate groups. The 
sulfur peaks observed at ~ 226.5 eV in Figures 25, 26 and 27 can-
not be from heparin sulfur and must therefore arise from sulfur 
in cysteine and cystine residues in the adsorbed proteins. The 
fact that no sulfur peaks are observed at ~ 232 eV can only be 
interpreted as evidence that heparin was not associated with the 
surface of the protein adsorbates. Rather, the immobilized hepa-
rin is covered by the absorbed protein layer. The high resolu-
tion sulfur 2S l /2 spectra for the heparinized diaminododecane 
derivatized surfaces after contact with ATIII, albumin and fi-
brinogen solutions are present in Figures 28, 29 and 30 respec-
tively. No peaks are observed near 232 eV, small peaks are ob-
served at ~ 226.5 eV. The same argument applies with these spec-
tra. Heparin sulfur is not present on the surface of the ad-
sorbed protein layers, what sulfur does appear must originate from 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































heparin is covered by the adsorbed protein. 
3.8.2 Heparinized Surfaces 
Exposed to Plasma 
127 
The elemental atomic percents calculated for heparin immobi-
lized to diaminobutane and diaminododecane derivatized cellulose 
surfaces after 2 hours exposure to plasma and subsequent rinsing 
are presented in Table XXII. 
The heparin immobilized to the diaminobutane cellulose, 
after plasma protein adsorption, produced the largest nitrogen 
content of any surface evaluated; almost twice the atomic percent 
of nitrogen. As with the prior section on protein adsorption 
from single component solutions, no sulfur 2S 1/2 peaks are ob-
served near 232 eV; instead, small peaks at ~ 277 eV are observed. 
Once again, this can only be interpreted as evidence that heparin 
was not associated with the surface of the protein adsorbate 
layers and must therefore be masked underneath the adsorbed pro-
teins. The high resolution sulfur 2S 1/2 spectra for heparinized 
diaminobutane and diaminododecane derivatized celluloses after 
plasma contact are presented in Figures 31 and 32 respectively. 
3.9 Platelet Retention and 
PF4 Release 
The fraction of platelets retained in the 1 cc gel volume of 
heparin immobilized diaminobutane and diaminododecane Sepharose 
6-MB gels are presented in Figure 33, the marker bars indicate 
one standard deviation. Platelet retention for diaminobutane and 





Atomic Percents of Heparinized 
Surfaces After Plasma Contact 
Cross Section- Number of 
Element Electron Type Scans 
S 1.43-25 50 
C 1.00-15 10 
N 1 .80-1 S 10 
0 2.93-15 10 
Diaminododecane S 1 .43-2S 50 
C 1 .00-1 S 10 
N 1 .80-1 S 10 
































































































































































































































































































































































































































































































































and untreated Sepharose 6-MB gels are also presented. The frac-
tion of platelets retained was calculated from the equation: 
Fraction Retained = 1 _ I (# platelets/mm3) test sample : I I i (# platelets/ mm3) baseline control I 
- ~ 
The initially high values for platelet retention associated with 
all materials in fraction #1 corresponds with hematocrit di1u-
tion; however, beginning with fraction #4, platelet retention for 
the diaminododecane derivatized gel significantly increases until 
76.8% ! 14.4% of the platelets are retained in the final whole 
blood fraction. These column were clotted at the end of the 25ml 
whole blood perfusion experiments. No significant differences in 
platelet retention were observed for any of the other gels. 
Platelet factor 4 levels in plasmas from whole blood fractions 
and in rinse buffers for the above gels are presented in Figure 
34. For a given fraction, untreated Sepharose 6-MB produced the 
least amount of PF4 release. 
The differences in PF4 release for the various fractions are 
statistically insignificant between the diaminobutane derivatized 
Sepharose 6-MB and both heparin immobilized Sepharoses, and these 
levels are only slightly higher than the corresponding fractions 
obtained with untreated Sepharose. However, all fractions col-
lected from the diaminododecane derivatized gels show signifi-
cantly higher levels of PF4 than corresponding fractions for all 
other gels. Platelet factor 4 levels are approximately three 
times higher in all whole blood fractions obtained for the di-

































































































































































































from other gels, and these elevated PF4 levels correspond with the 
increased platelet retention beginning with fraction #4. 
CHAPTER 4 
DISCUSSION 
4.1 Functional Group 
Derivatization 
Free amine groups of heparin can be blocked with no loss in 
anticoagulant activity. With this prior knowledge, all carboxylic 
and hydroxyl group derivatizations were subsequently conducted 
with N-acetylated heparin to prevent intra- and intermolecular 
crosslinking. It was found that the heparin carboxylic groups 
could be partially derivatized with only minimal losses in anti-
coagulant activity; however, the degree of derivatization was 
critical at a certain level. More than 50% derivatization with 
n-butylamine resulted in the complete loss of anticoagulant activ-
ity. Heparin carboxylic groups have been blocked by others (98), 
and those derivatized heparins possessed no anticoagulant activ-
ity. However, in those studies, only fully derivatized compounds 
were investigated and partially derivatized compounds were not 
evaluated. Interestingly, the end group on the derivatization 
ligand did not appear to greatly influence the resultant antico-
agulant activity. Both methyl end groups, n-butylamine reactions, 
and sulfate end groups, 2-aminoethyl hydrogen sulfate reactions, 
on respective carboxylic derivatized heparins showed anticoagulant 
activity under partial derivatization. 
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The same trend was observed for the hydroxyl derivatization 
reactions using two different crosslinking agents, epichlorohydrin 
and divinylsulfone. Although the degree of derivatization was not 
further investigated, partially derivatized heparins were found 
to be active; and the derivatization ligand end groups once again 
did not appear to greatly influence the resultant anticoagulant 
activity. Methyl end groups, n-buty1amine reactions, sulfate end 
groups, 2-aminoethyl hydrogen sulfate reactions, and carboxylic 
end groups, glycine reactions, on hydroxyl derivatized compounds 
all produced active heparin under partial derivatization condi-
tions. Since these hydroxyl derivatization reactions were con-
ducted with crosslinking agents, heparin crosslinking was a pos-
sibility that could not be dismissed. 
Because crosslinking would be a difficult parameter to con-
trol, the majority of immobilization reactions were conducted 
utilizing heparin carboxylic groups; although heparin immobiliza-
tion was endeavored via heparin hydroxyl groups using the cross-
linking agent divinylsulfone. Results from the n-butylamine 
derivatization of heparin carboxylic groups demonstrated that 
active immobilized heparin could be achieved were heparin immobi-
lized to aminoalkane spacer arms and if the number of heparin 
carboxylic groups participating in the amidation reaction was 
minimized. Amidation reactions with n-butylamine demonstrated 
that derivatized heparin was still active if approximately 20% of 
the total carboxylic groups were blocked. All heparin irnmobiliza-
tion reactions, involving the formation of an amide linkage be-
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ween heparin carboxylic groups and free surface associated amine 
groups, were conducted using sufficient quantitites of Woodward's 
Reagent K to activate a maximum of 20% of the total carboxylic 
groups assuming 100% efficiency in the overall immobilization 
scheme. 
4.2 Heparin Immobilization 
4.2.1 Heparin Immobilization to 
Diaminoalkpne Derivatized 
Agarose Beads 
Using reaction conditions such that a maximum of 20% of the 
heparin carboxylic groups participated in the immobilization reac-
tions, heparin was coupled to agarose beads via different length 
diaminoalkane derivatized agarose beads. The degree of heparin 
coupling to the diaminoalkane-agaroses appeared dependent upon 
the hydrocarbon length of the diaminoalkane spacer arm. Low de-
grees of heparin coupling were observed for a 2 carbon diamino-
alkane spacer arm (see Tables IV and VII). Heparin coupling, re-
lative to the surface concentration of diaminoalkane spacer arms, 
progressively increased with increased spacer arm length up to the 
8 carbon spacer arm, afterwhich immobilization progressively de-
creased with the 10 and 12 carbon spacer arms. The anticoagulant 
activity of the immobilized heparin, as determined by APTT meth-
ods, also appears dependent upon the spacer arm length. As shown 
in Figure 24 and in Table XIX, APTT was slightly greater than 
baseline control plasma APTT for heparin immobilized via 2, 4 and 
8 carbon spacer arms; however, beginning with the 10 carbon spacer 
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arm, APTT significantly increases over baseline values with in-
creasing spacer arm length. The increased clotting time response 
was dose dependent and higher clotting times could be achieved 
with greater surface areas. This increased APTT for plasmas ex-
posed to immobilized heparin surfaces could not be attributed to 
the release of free heparin. Scintillation counting of tritium 
labeled heparin in plasmas exposed to the immobilized heparin 
materials revealed some free heparin; however, those levels were 
far too low to produce the observed levels of prolonged clotting. 
Slightly elevated APTT times were also observed for plasmas ex-
posed to heparin immobilized to Sepharose 48 beads via divinyl-
sulfone, and these clotting times were similar to those observed 
for heparin immobilized to diaminoalkane-agaroses of comparable 
spacer arm length (see Table XIX). A question that arises is: 
are the increased clotting times due to II sol ution-like ll heparin 
interactions, interactions with ATIII and activated coagulation 
factors, or are the increased APTT due to nonspecific adsorption 
of clotting factors onto a highly negatively charged surface? 
Larsson, et ale (99) have shown clotting times to increase for 
plasmas exposed to sulfated surfaces; however, clotting times for 
plasmas with free sulfate, added in various concentrations, was 
not affected over a 1.5 X 10-2 M to 1.5 X 10-9 M concentration 
range. Furthermore, the elevated clotting times associated with 
plasma exposed to the sulfate surface could be neutralized by 
protamine, even though no heparin was used in the experiments. 
One might conclude that the increased clotting times might be 
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the result of this nonspecific coagulation factor depletion of the 
plasma following contact with the immobilized heparin materials. 
However, the dramatically increased clotting times associated with 
longer spacer arms must arise through more specific heparin inter-
actions. Schmer (84) provided evidence that immobilized heparin 
had better AT!II binding and subsequent thrombin neutralization 
for heparin immobilized via putrescine and s-amino capryol spacer 
arms. Perhaps this is what has occurred with the heparin immobi-
lized via 10 and 12 carbon diaminoalkane spacer arms. The conclu-
sion should not be drawn, however, that further increasing the 
length of the diaminoalkane spacer arm will necessarily result in 
still greater anticoagulant increases for immobilized heparin 
materials. With longer hydrocarbon diaminoalkane spacer arms, 
the surface becomes progressively more hydrophobic and wetting of 
the surface by the aqueous phase plasma will decrease. Also with 
longer hydrocarbon chains, folding can result and the actual 
spacer arm length may be substantially shorter than expected. 
These considerations have been addressed by Kim, et al. (100) who 
immobilized urokinase to Sepharose beads via different length 
aminoalkyl acid spacer arms. They too observed low immobiliza-
tion yields with shorter spacer arms, and the immobilization yield 
progressively increased with longer hydrocarbon lengths. The 
activity of the immobilized enzymes was also found to increase 
with 10nger aminoalkyl acid spacer arms; however, a maximum activ-
ity was observed with 8 carbon spacer arms and activity progres-
sively decreased with longer spacer arms. Those authors attri-
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buted this phenomena to the increased surface hydrophobicity with 
the 10 and 12 carbon spacer arms; but with the highly negatively 
charged heparin, the surface hydrophobicity associated with 10 and 
12 carbon diaminoalkane spacer arms may be negated. 
The significant difference between the immobilization of 
heparin reported in this dissertation and prior heparin immobi-
lization work reported in the literature lies in the control of 
the immobilization chemistry and in the characterization of spacer 
arm affects on the anticoagulant activity of the ·immobilized hep-
arin. In this study, thorough characterization of the immobiliza-
tion affects on the anticoagulant activity of heparin was evalu-
ated with the soluble heparin derivatization experiments. No 
other group has investigated the possible alterations on the anti-
coagulant activity that could result from immobilizing heparin via 
specific functional groups on heparin and tailored the immobili-
zation chemistry to simulate those control experiments where the 
anticoagulant activity was preserved. Also, prior investigations 
on immobilized heparin have not gone to such extremes to prevent 
heparin crosslinking during the immobilization reaction. By pre-
viously blocking primary amine groups on the heparin, crosslinking 
during the amidation coupling reactions is essentially eliminated. 
Numerous other prior investigations (78,79,88) have actually re-
lied on heparin crosslinking to immobilize the heparin to the re-
spective surfaces, yet no attempts were made to characterize the 
degree of crosslinking or the affect of such crosslinking on the 
anticoagulant activity of heparin. In addition, previous studies 
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in heparin immobilization have not systematically evaluated 
spacer arm effects on immobilized heparin activity, with the ex-
ception of Schmer, et al. (84). However, in those studies dif-
ferent types of spacer arms rather than different lengths of 
common spacer arms were studied. 
All further testing of immobilized heparin surfaces was con-
ducted on heparin immobilized to diaminobutane and diaminodode-
cane derivatized surfaces, these being representative short and 
long spacer arms producing slightly elevated and greatly elevated 
clotting times respectively. 
Although iQ vitro clotting times can be greatly increased by 
the presence of immobilized heparin, the thromboresistance of 
such surfaces in vivo remains in question. Platelet interactions 
with the immobilized heparin materials can control the overall 
thromboresistance. As stated in the Introduction, soluble hepa-
rin adversely affects platelets, resulting in aggregation and 
platelet release reactions. Plasma protein/surface interactions 
and platelet interactions with heparin immobilized to 4 carbon 
and 12 carbon diaminoalkane derivatized polymer was therefore in-
vestigated. Protein interactions with the immobilized heparin 
was investigated by XPS analysis of heparin surfaces, before and 
after exposure to protein solutions. Platelet retention and con-
comitant PF4 release were also investigated as described in Sec-
tion 2.12. All XPS analyses were conducted on flat geometry 
materials while all platelet studies were conducted on Sepharose 
6-MB beads. 
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4.2.2 XPS Analysis 
XPS analysis of the starting polymer substrate, cellulose, 
the diaminoalkane derivatized celluloses, heparin immobilized 
diaminoalkane celluloses and pure heparin powder was initially 
conducted. The low binding energy portions of the carbon lS 
electrons progressively increased with diaminobutane and diamino-
dodecane derivatization, as expected, and the sulfur 2S electrons 
were used as the IIheparin tag,1I By that, heparin sulfur is pre-
sent as either a sulfate or sulfamate. The sulfur 2S electrons 
on heparin therefore have higher binding energies due to the high 
electronegative environment for the heparin sulfur atoms. Sulfur 
2S electrons for heparin powder and for immobilized heparin sur-
faces occur at approximately 232 eV binding energy. No other 
sulfur atoms from proteins adsorbed onto heparinized surfaces 
should have 2S electron near 232 eV, rather they will occur at 
lower binding energies near 227 eV. 
Both heparinized cellulose sheet materials demonstrated 
~ 0.25 atomic percent sulfur. When compared to a pure heparin 
powder surface, 5.29 atomic percent sulfur, it appeared that 
there is approximately 5-10% heparin surface coverage with both 
immobilized heparin materials. This low value is reflected also 
by tritium labeled heparin immobilization experiments where immo-
bilization yields for heparin immobilization to flat geometry 
diaminoalkane-cellulose materials was also low relative to the 
bead geometries (see Tables VII, VIII and IX). 
After two hours contact with single component ATIII, albumin 
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and fibrinogen solutions, no sulfur 2S electron peaks are ob-
served near 232 eVe No sulfur 2S electron peaks are observed for 
heparinized diaminobutane or diaminododecane cellulose after 
ATI!I adsorption. A very small sulfur 2S electron peak is ob-
served for both heparinized materials near 227 eV after fibrino-
gen adsorption (~ 0.1 atomic percent sulfur) and a slightly 
larger sulfur 2S electron peak is also observed near 227 eV after 
albumin adsorption onto both heparinized materials (~ 0.2 atomic 
percent sulfur). No heparin sulfur was ever observed following 
protein adsorption from single component solutions. It must be 
concluded that heparin was not associated with the surfaces of 
the protein adsorbates and is instead covered by the adsorbed 
protein layer. It must be noted, however, that these results 
were obtained for dehydrate surfaces and hydrate surfaces might 
produce different results. The same phenomena was observed for 
heparinized diaminobutane and diaminododecane celluloses after 
plasma contact. No heparin sulfur 2S electron peaks are observed 
at 232 eV as was the case prior to plasma contact. Small sulfur 
2S peaks are observed near 227 eV for both heparin materials with 
0.2 and 0.1 atomic percents sulfur for the 4 carbon and 12 carbon 
spacer arms, respectively. Once again, heparin sulfur was not 
detected on the surface of the protein adsorbates, and it may be 
concluded that the immobilized heparin was covered by the ad-
sorbed proteins. These findings are contradictory to the Auger 
Electron Spectroscopy analyses of Eriksson, et al. (82). After 
plasma protein adsorption onto their immobilized heparin surfaces, 
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those investigators observed sulfur on the surface of the protein 
adsorbate, which they attributed to heparin migrating through the 
adsorbed protein to the surface of the adsorbate. 
Auger electron spectroscopy does not distinguish small 
changes in electron binding energy as does XPS and it is possible 
that those investigators were confusing sulfur from cysteine and 
cystine residues in plasma proteins for heparin sulfur. The XPS 
results report in this dissertation clearly demonstrate that the 
immobilized heparin was not able to penetrate adsorbed proteins 
and become associated with the surface of the protein layer, 
casting doubts on the hypothesis of Larsson (81) that the anti-
coagulant effect of immobilized heparin is due to its ability to 
migrate to the surface of the adsorbed protein layer and then in-
teract with free coagulation factors. The fact that immobilized 
heparin is masked by adsorbed proteins supports the contention 
that prolonged ~ vitro clotting times observed with immobilized 
heparin surfaces are the result of plasma depletion of coagula-
tion factors. The observation that the 12 carbon spacer arm im-
mobilized heparin after plasma contact was lower in sulfur at 
227 eV, 0.1 atomic percent, than the 4 carbon spacer arm immobi-
lized heparin, 0.2 atomic percent sulfur, would indicate that the 
protein layer adsorbed onto the 12 carbon spacer arm immobilized 
heparin contained more ATI!! than did the 4 carbon spacer arm 
immobilized heparin; no sulfur was detected near 227 eV with ad-
sorbed ATI!I. This possibility would support the APTT test re-
sults where it was hypothesized that heparin immobilized with the 
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longer spacer arms was preferentially interacting with ATIII and 
subsequent coagulation factors more specifically than heparin im-
mobilized with shorter spacer arms. 
4.3 Platelet Retention and 
PF4 Release 
Platelet interactions with a heparinized surface can playa 
major role in the ~ vivo thromboresistance of that surface. 
Soluble heparin has been shown to adversely interact with plate-
lets, resulting in aggregation and the release of endogenous 
platelet substances which can activate and accelerate thrombotic 
mechanisms. Platelet factor 4 is such a substance. Released 
from a-granules within the platelets, PF4 binds to and neutra-
lizes the anticoagulant activity of heparin; therefore, were 
platelets activated by immobilized heparin surfaces, PF4 could be 
released and bind to the immobilized heparin rendering the sur-
face ineffective with regards to heparin interactions with coagu-
lation factors. 
In these experiments, platelet retention and PF4 release 
were evaluated simultaneously using column techniques where whole 
blood was perfused through columns containing heparin immobilized 
beads. With this type of experimental setup, platelet retention 
values reflect both platelet adhesion onto the test materials and 
platelet aggregation in the plasma phase induced by the test 
materials, where platelet aggregates are retained based on size 
in the interstitial spacings between packed beads. In addition 
to providing information on the degree of PF4 binding to and neu-
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tralization of immobilized heparin, simultaneously conducting 
platelet retention and PF4 release experiments provides a more 
thorough characterization of platelet thrombotic effects associ-
ated with platelet/material interactions by demonstrating both 
platelet retention and platelet activation as indicated by PF4 
release. Platelet retention does not necessarily imply resulting 
thrombosis. 
Platelet factor 4 levels in whole blood exposed to heparin-
ized surfaces, and control surfaces, were therefore monitored to 
provide an indication of platelet activation and degranulation 
due to contact with various surfaces and to determine the amount 
of released PF4 bound to immobilized heparin surfaces. As shown 
in Figure 33, platelet retention for heparin immobilized to 4 
carbon and 12 carbon diaminoalkane derivatized Sepharose 6-MB 
beads is statistically indistinguishable; these values, for com-
parable fraction numbers, being also indistinguishable from un-
treated Sepharose 6-MB beads. The same response was observed for 
diaminobutane derivatized Sepharose 6-MB without immobilized hep-
arin; however, the diaminododecane derivatized beads produced 
significant platelet retention. The same trends were observed 
for PF4 release, as shown in Figure 34. Control Sepharose 6-MB 
elicited the least PF4 release while both heparinized materials 
were indistinguishable, with regards to PF4 release, for compar-
able fraction numbers. Once again, the diaminododecane deriva-
tized gels produced high levels of PF4 release, at least three 
times higher than all other materials evaluated. 
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The correlation between platelet retention and PF4 release 
provides documentation of the high thrombogenicity of the di-
aminododecane derivatized surfaces. The increased hydrophobic 
nature of the diaminododecane derivatized gels is the only para-
meter that differs between it and the diaminobutane derivatized 
gels, both surfaces having the same molar degree of diaminoalkane 
derivatization. These studies show that platelets are both re-
tained and activated by diaminododecane surfaces. Although 
spacer arm lengths affect in vi clotting times for immobilized 
--
heparin materials, platelet interactions were indistinguishable 
for the two spacer arms evaluated. This is not a totally unex-
pected result. As previously stated, the immobilized heparin was 
shown to be completely covered by the adsorbed protein layer; 
platelets do not IIsee" immobilized heparin. Rather, the nature 
of the adsorbed protein surface on top of the immobilized heparin 
controls platelet interactions. For this reason, immobilized hep-
arin might be more benign with regards to platelet interactions 
than soluble heparin. 
It is interesting to note that more PF4 was eluted off hep-
arin immobilized to the 12 carbon spacer arm than the 4 carbon 
spacer arm. With a molecular weight of ~ 27,000 (101), the 12 
- 11 '1 carbon spacer arm heparin bound ~ 2.3 X 10 moles of PF4, Whl e 
the 4 carbon spacer arm bound ~ 1.4 X 10-11 moles of PF4. As-
suming a molecular weight of 104 for the immobilized heparin, the 
-7 12 carbon and 4 carbon spacer arm materials both had ~ 1.5 X 10 
moles of immobilized heparin; therefore, much less than 1% of the 
immobilized heparin was neutralized by PF4 released during the 
whole blood perfusion experiments. 
4.4 Summary Conclusion 
From these studies, the following conclusions are made: 
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1. Primary amine groups on heparin can be blocked with no 
resultant loss in anticoagulant potency. Carboxylic and hydroxyl 
groups on heparin can be partially blocked with minimal resultant 
losses in anticoagulant activity; however, the degree of carboxy-
lic blocking is critical and more than approximately 50% blockage 
results in the total loss of anticoagulant activity. The end 
groups on ligands used to derivatize the carboxylic and hydroxyl 
groups appear to have little affect on the anticoagulant activity 
of partially derivatized heparins. At approximately 10 to 20% 
blockage of both carboxylic and hydroxyl groups; methyl, car-
boxylic and sulfate end groups on derivatized ligands all produce 
derivatized heparins with approximately 120 units/mg. The 
initial activity of the starting material heparin was approxi-
mately 155 units/mg. 
2. Based on prior n-butylamine blocking reactions of hepa-
rin carboxylic groups, heparin was immobilized via analogous re-
action schemes to diaminoalkane derivatized polymer substrates. 
The n-butylamine heparin amidation reactions showed that 20% 
blockage of the total heparin carboxylic groups resulted in ac-
tive heparin. The n-butylamine was used to mimic the diaminoal-
kane spacer arms used in the immobilization reactions where a 
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maximum of 20% of the total heparin carboxylic groups partici-
pated in the covalent surface immobilization, assuming 100% effi-
ciency for the immobilization reactions. The fact that 20% 
blockage of heparin carboxylic groups resulted in active heparin 
indicated that the immobilized heparin, also utilizing 20% of the 
total carboxylic groups, would be active. 
3. The heparin immobilization yields were found to be de-
pendent upon the diaminoalkane spacer arm length. Immobilization 
yields progressively increase with 2, 4 and 8 carbon spacer arms, 
the diaminooctane spacer producing the maximum immobilization 
yield. The immobilization yields then progressively decrease with 
10 and 12 carbon diaminoalkane spacer arms. 
4. It was found that APTT clotting times of plasma exposed 
to immobilized heparin materials were also dependent upon the 
length of the diaminoalkane spacer arm. Elevations in APTT, re-
lative to control plasma, were observed with 2, 4 and 8 carbon 
spacer arms; however, beginning with 10 carbon spacer arms, APTT 
dramatically increased, presumably due to more specific binding 
interactions with ATIII and subsequent coagulation factors. 
5. XPS analyses of immobilized heparin materials, with 4 
carbon and 12 carbon diaminoalkane spacer arms, before and after 
contact with single component solutions of ATIII, albumin and 
fibrinogen and with plasma revealed that heparin is covered by 
absorbed proteins and is not associated with the surface of the 
protein adsorbate. The nature of the adsorbed proteins, from 
contact with plasma, appears different for heparin immobilized by 
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4 carbon and 12 carbon diaminoalkane spacer arms. The 4 carbon 
spacer arm immobilized heparin produces a protein adsorbate 
higher in sulfur than the 12 carbon spacer arm immobilized hepa-
rin. Since it was demonstrated that adsorbed ATIII surfaces were 
essentially free of sulfur, this might indicate that the 12 car-
bon spacer arm immobilized heparin is preferentially interacted 
with ATIlT. 
6. Platelet retention and PF4 release were indistinguish-
able for heparin immobilized with 4 carbon and 12 carbon spacer 
arms and these responses were comparable to untreated Sepharose 
beads. The diaminododecane derivatized Sepharose produced high 
levels of platelet retention and PF4 release, these affects on 
platelet function being eliminated following heparin immobiliza-
tion. Since it was previously shown that heparin immobilized 
with 4 and 12 carbon spacer arms was covered by adsorbed proteins 
and therefore not able to directly interact with platelets, the 
fact that platelets did not adversely interact with immobilized 
heparin surfaces, as was feared based on the platelet behavior of 
soluble heparin, is understandable. 
7. Based on the amount of PF4 eluted off immobilized hepa-
rin materials by 1 M NaCl, less than 1% of the immobilized hepa-
rin was neutralized by PF4. Since relatively minor amounts of 
PF4 were released from platelets in whole blood following contact 
with immobilized heparin materials, this too is not totally un-
expected. 
8. Anticoagulant activity of immobilized heparin is depen-
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dent upon the spacer arm length while platelet interaction is in-
dependent of the spacer arm length. 
4.5 Proposed Future Studies 
4.5.1 Immobilization of Heparin 
Fractions 
All of the work reported in this thesis was conducted on un-
fractionated, bulk heparin. Numberous investigators have studied 
molecular weight fractions of heparin, inc1uding high ATIII af-
finity molecular weight fractions. In general, low molecular 
weight fractions have less anticoagulant activity but improved 
platelet interactions than do the high molecular weight frac-
tions. An exception to this rule of thumb is the low molecular, 
high ATIII affinity heparin fractions which possess high antifac-
tor Xa activity. Since platelet interactions with immobilized 
bulk heparin, ranging in mo1ecular weight from less than 10,000 
to greater than 20,000, have been demonstrated to be relatively 
benigh, presumably due to the fact that the immobilized heparin 
was covered with adsorbed proteins that did not adversely inter-
act with platelets, significant improvements in platelet inter-
actions might not be achieved by immobilizing low molecular 
weight heparin fractions. However, improved intrinsic coagula-
tion factor interactions might be achieved through the immobili-
zation of high ATIII affinity fractions. It is therefore pro-
posed that such high ATIII affinity fractions be isolated and im-
mobilized for further thromboresistance characterizations using 
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both high (> 20,000) and low « 10,000) molecular weight high af-
finity fractions. 
4.5.2 Protein Adsorption 
Isotherms 
The nature of the proteins adsorbed onto the heparinized 
materials is of great importance in the thromboresistance of such 
surfaces. Increased anticoagulant activity of immobilized hepa-
rin with increased spacer arm length was observed. It was hypo-
thesized that this effect was due to increased ATllI interactions 
with the longer spacer arms, yet this hypothesis was not proven. 
It is therefore proposed that competitive adsorption isotherms be 
conducted with purified radiolabeled ATIII, albumin and fibrino-
gen solutions (three separate solutions where only one protein is 
labeled) for heparin immobilized via diaminobutane and diamino-
dodecane spacer arms. It would also be interesting to conduct 
platelet adhesion studies on adsorbed ATIII surfaces. Benign 
platelet interaction has typically been attributed to albumin 
adsorption; however, platelet interaction with adsorbed ATIII 
surfaces has not been investigated. At a plasma concentration 
near 0.2 ~g/ml ATlll is a relatively abundant plasma protein that 
could also be adsorbing onto materials to produce benign surfaces 
with regards to platelet interaction. 
4.5.3 In Vivo Characterization 
Finally, both acute and chronic ~ vivo thromboresistance 
characterization studies should be conducted. Parameters that 
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should be investigated during this phase of experimentation 
should include, the ~ vivo stability of the immobilized heparin 
(the heparin is coupled by a degradable amide bond) and evalua-
tions of surface thrombosis on heparinized materials following 
venous implantation. 
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